Research Poster Presentations - Session II

Monday, May 18, 2015
3:45PM-7:45PM

Poster Author Discussion Hour:
6:45PM-7:45PM

Research Poster Presentations – Session II includes the following topics

- PHP – HEALTH CARE USE & POLICY STUDIES  Rows A- K
- PIH – INDIVIDUAL’S HEALTH  Rows K-N
- PMH – MENTAL HEALTH  Rows N-W

A1  Location of the poster in the poster hall – please refer to last page for a floor plan
pgA10  Location of the abstract as published in Value in Health Volume 18, Issue 3
HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care

PHP1 A1 pgA71 ASSOCIATION BETWEEN INFORMAL CAREGIVERS’ ASSISTANCE IN MANAGEMENT OF CARE-RECIPIENTS’ MEDICATIONS AND THEIR USE OF TRAINING SERVICES- A NATIONAL RETROSPECTIVE STUDY

Noureldin M1, Murawski M2, Mason H2, Hyner G3, Plake K1, Purdue University College of Pharmacy and Center on Aging and the Life Course, West Lafayette, IN, USA, 4Purdue University College of Pharmacy, West Lafayette, IN, USA, 5Purdue University College of Health and Human Sciences and Center on Aging and the Life Course, West Lafayette, IN, USA

PHP2 A2 pgA71 PATIENTS SENT TO THE EMERGENCY DEPARTMENT BY ADVANCED HEALTHCARE PROVIDERS ARE MORE LIKELY TO NEED ADMISSION

Groner K1, Lange CE1, Davis B1, Bounds RB2, 3Christiana Care Health System, Newark, DE, USA, 2Sidney Kimmel Medical College, Philadelphia, PA, USA

HEALTH CARE USE & POLICY STUDIES - Diagnosis Related Group

PHP3 A3 pgA71 THE EFFECT OF DRG-BASED PERFORMANCE- VOLUME LIMIT ON THE ANNUAL BUDGET OF THE CLINICAL CENTRE OF UNIVERSITY OF PÉCS IN HUNGARY

Endrei D1, Agoston I1, Csákóvári T1, Répásy B1, Molics B1, Danku N1, Vajda R1, Boncz I1, University of Pécs, Pécs, Hungary, 4University of Pécs, Zalaegerszeg, Hungary

HEALTH CARE USE & POLICY STUDIES - Disease Management

PHP4 A4 pgA71 PREVENTABLE HOSPITALIZATIONS AMONG WEST VIRGINIA MEDICAID BENEFICIARIES WITH CHRONIC CONDITIONS

Agarwal P1, Bose S1, Bias T1, Sambamourthi U, West Virginia University, Morgantown, WV, USA

PHP5 A5 pgA71 PREPARATION OF A DATASET FOR ANALYSIS TO DEVELOP A PREDICTOR ALGORITHM FOR DISEASE STATE MANAGEMENT

Lovett AW1, Chaturvedula A2, Mukherjee K2, Brar A2, Tamhankar N2, 1Mercer University, Atlanta, GA, USA, 2GVK Biosciences, Hyderabad, India

PHP6 A6 pgA72 DISPARITIES IN PATIENT RESPONSE TO POTENTIAL ADVERSE DRUG EFFECT

Ning N1, Lu Y2, Gascue L1, Ding Y1, Joyce G1, 1University of Southern California, Los Angeles, CA, USA, 2Harbor-UCLA Medical Center, Torrance, CA, USA

PHP7 A7 pgA72 PATIENT AWARENESS AND USE OF MEDICATION GUIDES

Walton A1, Paul K2, 1United BioSource Corporation, Blue Bell, PA, USA, 2The Corvallis Group, LLC, Summit, NJ, USA

PHP8 A8 pgA72 PERCEPTIONS OF COMMUNITY PHARMACISTS ABOUT THEIR CURRENT PROFESSIONAL ROLE, INTER PROFESSIONAL LEARNING AND CONTINUE PROFESSIONAL DEVELOPMENT IN PAKISTAN

Iqbal MS1, Iqbal MZ2, Iqbal MW3, Ping NY4, Bahari MB2, 1Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan, Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 2Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia, 3Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 4Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia, 5Faculty of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 6Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

PHP9 A9 pgA72 KNOWLEDGE, ATTITUDE AND PERCEPTIONS OF HOSPITAL PHARMACISTS TOWARDS PHARMACISTS LED INTERVENTIONS TO REDUCE ADVERSE DRUG REACTIONS, DRUG INTERACTIONS, AND PHARMACEUTICAL CARE ISSUES TOWARDS BETTER PHARMACEUTICAL CARE PLANNING: A QUALITATIVE INSIGHT FROM PAKISTAN

Iqbal MS1, Iqbal MW2, Iqbal MZ2, Akhtar N1, Ping NY2, Bahari MB3, 1Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan, Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 2Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia, 3Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 4Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy

PHP10 A10 pgA72 TRACKING THE SPONSORING COUNTRY OF INCORPORATION FOR NEW DRUGS APPROVED BY THE US FDA IN THE PERIOD 1980-2014: A TREND ANALYSIS

Alqahtani SS1, Rodriguez-Monguio R2, Seoane-Vazquez E3, Eguale T4, Zeukeng S5, Szeinbach S6, 1MCPHS University, Boston, MA, USA, 2University of Massachusetts, Amherst, Amherst, MA, USA, 3Brigham and Women’s Hospital, Boston, MA, USA, 4University of Geneva, Geneva, Switzerland, 5Ohio State University, Columbus, OH, USA

PHP12 A11 pgA72 THE IMPACT OF THE ESSENTIAL MEDICINE POLICY ON PATIENTS’ HEALTH CARE UTILIZATION AND
COST IN TIANJIN CHINA: A QUASI-EXPERIMENTAL DESIGN
Ding L, Wu J, Tianjin University, Tianjin, China

PHP14 A12 pgA73 IMPACT OF 2014 ESSENTIAL HEALTH BENEFIT BENCHMARK PLANS ON US MANAGED CARE
Aggarwal S, Topaloglu H, NOVEL Health Strategies, Chevy Chase, MD, USA

PHP15 A13 pgA73 AN ASSESSMENT OF THE THERAPEUTIC BIOLOGIC PRODUCTS LICENSED BY THE FDA AND THE EMA
Grozdanova A, Olasupo O, Seoane-Vazquez E, Faculty of Pharmacy UKIM, Skopje Macedonia, Skopje, Macedonia, Massachusetts College of Pharmacy & Health Sciences, Boston, MA, USA, MCPHS University, Boston, MA, USA

PHP17 A14 pgA73 THE IMPACT OF NEW DRUG PRICING POLICY ON MARKET COMPETITION AMONG OFF-PATENT DRUGS IN SOUTH KOREA
Kwon H, Kim H, R. Reich M, Harvard T.H. Chan School of Public Health, Boston, MA, USA, National Health Insurance Service, Seoul, South Korea

PHP18 A15 pgA73 THE ROLE OF COST-EFFECTIVENESS STUDIES IN DRUG PRICING DECISIONS: A CASE REVIEW FROM JORDAN

PHP19 A16 pgA73 THE DIFFERENCE BETWEEN THE MAXIMUM RETAIL PRICE AND TENDER PRICE: A COMPARATIVE STUDY ON BRANDNAME AND GENERIC DRUGS
Liu B, Department of Health Economics, School of Public Health, Fudan University, Shanghai, China

PHP20 A17 pgA73 ANALYSIS OF THE DRUG PRICE REVIEWS PERFORMED BY THE CANADIAN PATENTED MEDICINE PRICES REVIEW BOARD (1998-2014)
Alsumali A, Seoane-Vazquez E, Egualte T, Mekary R, MCPHS University, Brighton, MA, USA, MCPHS University, Boston, MA, USA, MCPHS University, N/A, MA, USA

PHP21 A18 pgA74 CHANGES OF THE HUNGARIAN HEALTH INSURANCE PHARMACEUTICAL BUDGET BETWEEN 2007-2013

PHP22 A19 pgA74 EFFECT OF THE U.S.-PERU FREE TRADE AGREEMENT ON PERUVIAN NEW DRUG POLICIES AND THE REGISTRATION OF PHARMACEUTICAL PRODUCTS
Araujo LE, Montagne M, MCPHS University, Boston, MA, USA

PHP23 A20 pgA74 THE CHARACTERISTICS OF PHARMACY AND THERAPEUTIC COMMITTEES IN SAUDI HOSPITALS
Alkelya M, Alenezi MG, Alsultan MM, AlJerayis M, King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia, King Saud University, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Riyadh, Saudi Arabia

PHP24 A21 pgA74 PRINCIPLES OF POLICY FRAMEWORK IN THE PHARMACEUTICAL WHOLESALE AND RETAIL SYSTEM IN LOWER INCOME EUROPEAN COUNTRIES
Inotai A, Csanadi M, Hanko B, Kalo Z, Syreon Research Institute, Budapest, Hungary, Semmelweis University Faculty of Pharmacy, Budapest, Hungary, Eötvös Loránd University, Faculty of Social Sciences, Budapest, Hungary

PHP25 B1 pgA74 ORPHAN AND ULTRA-ORPHAN TECHNOLOGIES IN THE NEW ERA OF PAYMENT REFORM: UNITED STATES PAYER PERCEPTIONS
Hogue S, Brogan AP, Croft E, RTI Health Solutions, Research Triangle Park, NC, USA, RTI-Health Solutions, Research Triangle Park, NC, USA, RTI-Health Solutions, Manchester, UK

PHP26 B2 pgA75 BREAKTHROUGH THERAPY STATUS – EXPEDITED FDA REGULATORY APPROVAL BUT WHAT ABOUT THE PAYERS?

PHP27 B3 pgA75 A NECESSARY CONVERGENCE? US PAYERS ADOPTING EU BEHAVIORS

PHP28 B4 pgA75 UNITED STATES DECISION MAKER PERCEPTIONS OF DATA FROM OBSERVATIONAL STUDIES AND OTHER HEALTH ECONOMICS AND OUTCOMES RESEARCH
Brogan AP, Hogue S, Mordin M, Kwong J, RTI Health Solutions, Research Triangle Park, NC, USA, RTI Health Solutions, Ann Arbor, MI, USA, Daiichi Sankyo, Parsippany, NJ, USA

PHP29 B5 pgA75 EVIDENCE THAT WEREWOLVES AFFECT THE NICE APPRAISAL PROCESS

PHP30 B6 pgA75 CHARACTERISTICS OF NURSING ASSOCIATED WITH COMPLETION OF COMPLIANCE MONITORING PROGRAM FOR SUBSTANCE ABUSE
Bhounsule P, Moes S, Peterson AM, University of the Sciences in Philadelphia, Philadelphia, PA, USA, Livengrin Foundation, Inc., Bensalem, PA, USA, University of the Sciences, Philadelphia, PA, USA

PHP31 B7 pgA75 FDA BREAKTHROUGH THERAPY STATUS - A SYSTEMATIC ANALYSIS OF ALL THERAPIES APPROVED
UNDER THIS NEW EXPEDITED APPROVAL PATHWAY
Macaulay R, PAREXEL, London, UK

PHP32 B8 pgA76 PROFILE OF DEMANDED MEDICINES AND INFLUENCE OF INTELLECTUAL PROPERTY RIGHTS PROTECTION IN MINAS GERAIS, BRAZIL
Nascimento RC1, Guerra Junior AA1, Silva RL2,1, College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2Law School, Federal University of Minas Gerais, Belo Horizonte, Brazil

PHP33 B9 pgA76 COMPETITION AND STRATEGIC REGULATION IN THE ARGENTINE PHARMACEUTICAL MARKET. A COMPARATIVE STUDY OF SIX THERAPEUTIC CLASSES
Maceira D, Palacios A, Center for the Study of State and Society (CEDES), Buenos Aires, Argentina

PHP34 B10 pgA76 AN ANALYSIS OF WARNING LETTERS ISSUED TO PHARMACEUTICAL COMPANIES REGARDING MISLEADING HEALTH OUTCOMES CLAIMS 2009-2013
Lionnet L, Fader A, MedVal Scientific Information Services, Skillman, NJ, USA

PHP35 B11 pgA76 CHARACTERISTICS OF PRODUCTS WITH PRICE CHANGES AFTER A POLICY CHANGE IN EGYPT
Mohamed O1, Kreling D2,3, Merck & Co. Inc., Lebanon, NJ, USA, 2School of Pharmacy, Madison, WI, USA

PHP37 B12 pgA76 A FRAMEWORK FOR STRENGTHENING PHARMACEUTICAL MANUFACTURING IN SUB-SAHARAN AFRICA
Mann M1, Adamson BJ1, Rennie T2, Stergachis A2,1, University of Washington, Seattle, WA, USA, 2University of Namibia, Windhoek, Namibia

PHP38 B13 pgA76 DEVELOPING ALGORITHMS FOR IDENTIFYING BENEFICIARIES WITH HIGHER THAN EXPECTED UTILIZATION OF OPIOIDS ANALGESICS
Verma D1, Banahan III B3, Hardwick SP3, Clark JP2,1, University of Mississippi, Oxford, MS, USA, 2University of Mississippi, University, MS, USA, 3Mississippi Division of Medicaid, Jackson, MS, USA

PHP39 B14 pgA77 THE USE OF PHARMACY CLAIMS DATA AS AN EARLY INDICATOR OF BIOEQUIVALENCE ISSUES FOR NEWLY LAUNCHED GENERIC MEDICATIONS
Levin R1, Cosmatos I1, Germscheid LM1, Frazee S2, Dieck G1, Murray R1, Patel A1, Henderson R2,1, United BioSource Corporation, Blue Bell, PA, USA, 2Express Scripts, St. Louis, MO, USA

PHP40 B15 pgA77 FEDERAL EXCHANGES PROVIDE LOWER PREMIUMS BUT LESS GENEROUS PHARMACY BENEFITS THAN EMPLOYER-SPONSORED PLANS

PHP41 B16 pgA77 SUBSTANCE USE ADMISSIONS TREND AMONG OLDER ADULTS
Chhatre S1, Metzger DS, Jayadevappa R, University of Pennsylvania, Philadelphia, PA, USA

PHP42 B17 pgA77 ANTIMICROBIAL UTILISATION IN SLOVAK HOSPITALS
Snopkova M1, Antlova K1, Majtas J1, Faculty of Pharmacy Comenius University, Bratislava, Slovak Republic, 2Comenius University, Bratislava, Slovak Republic

PHP43 B18 pgA77 DRUG RELATED PROBLEMS, PRESCRIBING PATTERN AND POLYPHARMACY: EVIDENCE FROM COMMUNITY PHARMACIES IN PAKISTAN
Iqbal MS1, Iqbal MZ2, Iqbal MW3, Akhtar N1, Bahari MB2,1, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMS University, Kedah, Malaysia, 2Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMS University, Kedah, Malaysia, 3Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia, 4Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan, 5Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMS University, Kedah, Malaysia

PHP44 B19 pgA78 PATIENTS’ PERCEPTION AND KNOWLEDGE OF ADVERSE DRUG REACTIONS ASSOCIATED WITH HERBAL MEDICINES
Bhat B, Dharmagadda S, Nayanabhirama U, Manipal University, Manipal, India

HEALTH CARE USE & POLICY STUDIES - Equity and Access

PHP45 B20 pgA78 IMPACT OF MEDICAID MANAGED CARE EXPANSION ON ACCESS TO PROVIDERS IN MISSISSIPPI
Shahpurwala Z1, Ramachandran S1, Banahan III B1, Hardwick SP2,1, University of Mississippi, University, MS, USA, 2Mississippi Division of Medicaid, Jackson, MS, USA

PHP46 B21 pgA78 GEOGRAPHICAL ACCESSIBILITY TO COMMUNITY AND HOSPITAL PHARMACIES IN HAMILTON COUNTY
Gangal NS1, Widener M, Kelton C, Heaton PC, University of Cincinnati, Cincinnati, OH, USA

PHP47 C1 pgA78 ANALYSIS OF MEDICINES CENTRALLY AUTHORISED BY THE EUROPEAN MEDICINES AGENCY (EMA) IN THE CONTEXT OF THEIR REIMBURSEMENT IN POLAND
Sujkowska G1, Jagodzińska-Kalinowska K1, Matusewicz W1, Zabielska J1, Agency for Health Technology Assessment and Tariff System, Warsaw, Poland

PHP48 C2 pgA78 ARE WE REALLY MEASURING ACCESS? SYSTEMATIC REVIEW OF ACCESS MEASURES TO MEDICINES IN BRAZIL
HEALTH CARE USE & POLICY STUDIES - Formulary Development

PHP55 C9 pgA79 IMPACT OF COST SHARING INCREASES UNDER PART D SPECIALTY TIERS ON BIOLOGIC ADHERENCE AND DISCONTINUATION AMONG MEDICARE BENEFICIARIES WITH MULTIPLE SCLEROSIS OR RHUMATOID ARTHRITIS

Li P1, Hu T1, Yu X1, Chahin S2, Dahodwala NA1, Doshi JA1, University of Pennsylvania, Philadelphia, PA, USA, 2University of Pennsylvania Health System, Philadelphia, PA, USA

PHP56 C10 pgA80 ASSESSING THE GENEROSITY OF DRUG COVERAGE IN THE HEALTH INSURANCE EXCHANGES

PHP57 C11 pgA80 THE UPTAKE OF BIOSIMILAR PRODUCTS BY BRITISH FORMULARIES

Alnahar S, Elliott R, Smith M, University of Nottingham, Nottingham, England

PHP58 C12 pgA80 IMPACT OF COST SHARING ON SPECIALTY DRUG UTILIZATION AND OUTCOMES: A REVIEW OF THE EVIDENCE AND FUTURE DIRECTIONS

Doshi JA1, Li P1, Ladage VP1, Taylor EA2, University of Pennsylvania, Philadelphia, PA, USA, 2RAND Corporation, Santa Monica, CA, USA

PHP59 C13 pgA80 WHEN IS HEALTH ECONOMICS AND OUTCOMES RESEARCH EVIDENCE IMPORTANT TO U.S. PAYERS?

Bajaj PS1, Willke RJ2, Basu A1, Sullivan SD1, Garrison LP2, University of Washington, Seattle, WA, USA, 1Pfizer, Inc., New York, NY, USA

PHP60 C14 pgA80 THE CALIFORNIAN TECHNOLOGY ASSESSMENT FORUM – THE ARRIVAL OF COST-UTILITY APPRAISALS OF DRUGS IN THE USA?

Macaulay R, Mistry J, PAREXEL, London, UK

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management

PHP61 C15 pgA81 HEALTHCARE RESOURCE UTILIZATION AMONG HISPANIC ADULTS RELATIVE TO NON-HISPANIC WHITE ADULTS IN THE US

Hoppes M, Udall M, Makinson G, McDonald M, Mardekin J, Pfizer Inc., New York, NY, USA

PHP62 C16 pgA81 POTENTIAL SAVINGS FROM A 15-DAY INITIAL FILL POLICY FOR SELECTED OUTPATIENT MEDICATIONS IN A STATE MEDICAID PROGRAM

Shahpura Z1, Ramachandran S1, Banahon III B1, Hardwick SP2, Clark JP1, University of Mississippi, University, MS, USA, 2Mississippi Division of Medicaid, Jackson, MS, USA

PHP63 D1 pgA81 EVALUATING THE COST OF PATIENT-CENTERED MEDICAL HOME TRANSFORMATION IN SMALL PRIMARY CARE PRACTICES

Vegesna A, Lieberthal RD, Payton C, Sarfaty M, Valko G, Thomas Jefferson University, Philadelphia, PA, USA

PHP64 D2 pgA81 A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSIS (CEA) STUDIES FROM THE PATIENT’S PERSPECTIVE
TPHP65  D3  pgA81  EFFECT OF PATIENT'S COST SHARING ON EXPENDITURES: AN INSTRUMENTAL VARIABLES APPROACH
Kawatkar AA, Kaiser Permanente Southern California, Pasadena, CA, USA

TPHP66  D4  pgA81  ECONOMIC IMPACT OF WASTE IN PRESCRIBING, DISPENSING, AND MEDICATION CONSUMPTION IN THE UNITED STATES
Almanie SA, Holdford DA, Virginia Commonwealth University, Richmond, VA, USA

TPHP67  D5  pgA82  IMPACT OF POST-SURGICAL COMPLICATIONS ON HOSPITAL COSTS AND MARGINS
Bao J1, Lavender R1, Chapman R1, Avalere Health, Washington, DC, USA, 2Edwards Lifesciences, Irvine, CA, USA

TPHP70  D6  pgA82  WHO IS SPENDING WHERE: ANALYSIS OF HEALTHCARE SPENDING BY MEDICAID AND PRIVATE PAYERS IN MASSACHUSETTS
Olchanski N1, Rane PB1, Cohen JT1, Neumann PJ2, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA, 3Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

TPHP71  D7  pgA82  PRODUCTIVITY GROWTH IN CALIFORNIA HOSPITALS FROM 2005 THROUGH 2011
Cheng W1, Romley JA, University of Southern California, Los Angeles, CA, USA

TPHP72  D8  pgA82  IMPACT OF THE SHIFT TO MEDICAID MANAGED CARE ON RESOURCE UTILIZATION AND COSTS FOR BENEFICIARIES IN MISSISSIPPI MEDICAID
Ramachandran S1, Banahan III B1, Hardwick SP2, Clark JP2, University of Mississippi, University, MS, USA, 3Mississippi Division of Medicaid, Jackson, MS, USA

TPHP73  D9  pgA83  PUBLISHED COSTS OF MEDICATION ERRORS LEADING TO PREVENTABLE ADVERSE DRUG EVENTS IN US HOSPITALS
Pan J1, Mays R2, Gill S3, Albert NM1, Patel D2, Stephens J2, Rocha-Cunha C1, Pulgar S1, Becton Dickinson, Franklin Lakes, NJ, USA, 2Pharmerit International, Bethesda, MD, USA, 3University of Pittsburgh, Pittsburgh, PA, USA, 4Cleveland Clinic, Cleveland, OH, USA

TPHP74  D10  pgA83  THE FINANCIAL IMPACT OF BLOOD SPECIMEN REJECTION DUE TO THE POOR PRE-ANALYTICAL QUALITY IN HEALTHCARE FACILITY IN CHINA
Liu Y1, Ren X1, Shenyang Pharmaceutical University, Shenyang, China, 2BD China, Shanghai, China

TPHP75  D11  pgA83  REGIONAL VARIATION IN CATASTROPHIC HEALTH CARE SPENDING IN PAKISTAN
Jahangeer RA, Pakistan Institute of Development Economics (PIDE), Islamabad, Pakistan

TPHP76  D12  pgA83  A LITERATURE REVIEW AND MICRO COSTING APPROACH TO DETERMINE THE COST OF ONE HOUR OF OPERATING TIME IN CANADA
Goldstein LJ1, Ondrejicka DA, Johnson and Johnson Medical Companies, Markham, ON, Canada

TPHP77  D13  pgA83  CURRENT ESTIMATES OF THE PUBLIC PHARMACEUTICAL EXPENDITURE IN MONGOLIA
Dori G, Mongolian University of Medical Sciences, Ulaanbaatar, Mongolia

TPHP78  D14  pgA83  CROSS SECTION ANALYSIS OF MARGINAL NHS EXPENDITURE BY ENGLAND HEALTH AREA

TPHP79  D15  pgA84  MEDICATION USE SURVEY OF INPATIENTS WITH BASIC MEDICAL INSURANCE FROM 2010 TO 2012
Xiong X1, Li J1, Zhang J1, Ma Y1, Gao SQ2, Yang L2, China Health Insurance Research Association, Beijing, China, 3Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China

TPHP80  D16  pgA84  WHICH DISEASES ARE DRIVING THE INCREASE IN SPENDING FOR THE PRIVATELY INSURED POPULATION OF THE US?
Marder WD, Huse DM, Truven Health Analytics, Cambridge, MA, USA

TPHP81  E1  pgA84  ACA'S IMPACT ON MERGERS AND WELLNESS: ASSESSING VALUE FOR MONEY
Vu M1, Lovett AW1, Kelley VP2, Hopper J1, Liu C1, 1Mercer University, Atlanta, GA, USA, 2Piedmont Healthcare, Atlanta, GA, USA

TPHP82  E2  pgA84  IMPACT OF CLINICAL AND HEALTH ECONOMIC PUBLICATIONS ON COMMERCIAL SUCCESS OF PHARMACEUTICAL PRODUCTS IN THE U.S
Stelko JP1, Basu A1, Sullivan SD1, University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Washington, Seattle, WA, USA, 3University of Washington School of Pharmacy, Seattle, WA, USA

TPHP83  E3  pgA84  PREVALENCE OF MEDICATION USE NOT CAPTURED BY PRESCRIPTION CLAIMS DATABASES – AN ANALYSIS USING 2012 MEDICAL EXPENDITURE PANEL SURVEY DATA
Electricwala B1, Carroll NV2, Virginia Commonwealth University, Richmond, VA, USA, 2Virginia Commonwealth University, Richmond, VA, USA

TPHP84  E4  pgA84  IMPROVED HEOR WRITING SKILLS OF KEEN INTEREST TO BIO/PHARMA HEOR DIRECTORS AND MANAGERS
ADVANTAGE PLANS IN TEXAS
Ferreira CN, Bethesda, MD, USA
THE VALUE OF BREAKTHROUGH THERAPY DESIGNATIONS
Comparative

Saggia M

KEY TRENDS IN HEALTHCARE SPENDING IN BRAZIL IN 2015
Liu Y

Westrich KD

DECISION COMPARATIVE EFFECTIVENESS RESEARCH (CER) AND ITS EFFECT ON THE HEALTH CARE
Piscataway, NJ, USA

Goyat R

RACIAL/ETHNIC DISPARITIES IN DISABILITY PREVALENCE
Oreagba IA

AN INTENSIVE STUDY OF ADVERSE EVENTS IN THE MEDICAL UNIT OF A NIGERIAN TEACHING
University, Philadelphia, PA, USA

Vegesna A

ELDERLY AND HOSPITALIZATION AND MORTALITY? A LONGITUDINAL, LARGE COHORT STUDY

IS THERE AN ASSOCIATION BETWEEN POTENTIALLY INAPPROPRIATE PRESCRIBING IN THE
AND OTC PRODUCTS

Drake T, Peeples P, Smalarz A, McClain B, Global Outcomes Group, Reston, VA, USA, HealthEconomics.com, Ponte Vedra Beach, FL, USA, Strategic Market Insight, Acton, MA, USA, Grapheme Consulting, Greensboro, NC, USA

PHP85 E5 pgA85 COMMUNICATING RISK OF MEDICATION SIDE EFFECTS: HOW RARE IS ‘RARE’ AND HOW LIKELY IS ‘LIKELY’?
Sawant RV, Sansgiry SS, University of Houston, Houston, TX, USA

PHP86 E6 pgA85 THE NUTRITIONAL STATUS OF ORPHANS AND CHILDREN LEFT WITHOUT PARENTAL CARE IN THE
CHILDREN’S HOMES OF THE HEALTH SYSTEM IN KAZAKHSTAN
Turgambayeva A, Bukeyeva Z, Suleimenova R, Syzdykova A, Astana Medical University, Astana, Kazakhstan, Child-Nutrition Fund, Almaty, Kazakhstan

PHP87 E7 pgA85 WHAT FACTORS MAKE ECONOMIC EVALUATION MORE VALUABLE AS A SERVICE?
Page K, Merlo G, Ratcliffe J, Halton K, Graves N, Queensland University of Technology, Brisbane, Australia, Flinders University, Adelaide, Australia

PHP88 E8 pgA85 REAL WORLD DATA FOR HEALTH AND TECHNOLOGY ASSESSMENT IN BRAZIL: AN UNMET NEED
Minowa E, Piedade A, Julian G, Evidências - Kantar Health, Campinas, Brazil, Evidências - Kantar Health, São Paulo, Brazil

PHP89 E9 pgA85 USE OF LOW-COST GENERIC PROGRAMS IN A NATIONALLY REPRESENTATIVE MEDICARE
POPULATION AND IMPLICATIONS FOR QUALITY INITIATIVES
Pauly N, Brown J, University of Kentucky, Lexington, KY, USA

PHP90 E10 pgA86 RELATIONSHIP BETWEEN THE DEVELOPMENT OF ELECTRONIC HEALTH RECORDS AND HOSPITAL
ACCREDITATION DECISIONS IN FRANCE: RESULTS FROM THE E-SI (PREPS-SIPS) STUDY
Perrier L, Havet N, Durand T, Caquot N, Amaz C, Biron P, Philip I, Cancer Centre Léon Bérard, Lyon, France, University Lyon 2, Lyon, France

PHP92 E11 pgA86 SERIOUS ADVERSE DRUG EVENTS REPORTED TO THE FOOD AND DRUG ADMINISTRATION (FDA):
ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) 2006-2011 DATABASE
Sonawane KB, Hansen RA, Auburn University, Auburn, AL, USA

PHP93 E12 pgA86 SENSITIVITY, SPECIFICITY AND LEVEL OF AGREEMENT BETWEEN DIFFERENT CRITERIA USED TO
DIAGNOSE THE METABOLIC SYNDROME
Bhounsule P, Peterson AM, University of the Sciences in Philadelphia, Philadelphia, PA, USA, University of the Sciences, Philadelphia, PA, USA

PHP94 E13 pgA86 IN THEIR OWN WORDS: SOCIAL LISTENING FOR “REAL-WORLD BENEFITS” FROM PRESCRIPTION
AND OTC PRODUCTS
Powell GE, Duke SP, Bell HG, Anderson LS, Metcalf MA, GSK, RTP, NC, USA

PHP95 E14 pgA86 IS THERE AN ASSOCIATION BETWEEN POTENTIALLY INAPPROPRIATE PRESCRIBING IN THE
ELDERLY AND HOSPITALIZATION AND MORTALITY? A LONGITUDINAL, LARGE COHORT STUDY
Vegesna A, Alcusky MJ, Keith SW, Hegarty SE, Del Canale S, Lombardi M, Maio V, Thomas Jefferson University, Philadelphia, PA, USA, Parma Local Health Authority, Parma, Italy

PHP96 E15 pgA86 AN INTENSIVE STUDY OF ADVERSE EVENTS IN THE MEDICAL UNIT OF A NIGERIAN TEACHING
HOSPITAL
Oregbua IA, Bada SO, Chuka-Ebene V, University of Lagos, Lagos, Nigeria

PHP97 E16 pgA87 RACIAL/ETHNIC DISPARITIES IN DISABILITY PREVALENCE
Goyat R, Vyasa A, Sambamoorthi U, West Virginia University, Morgantown, WV, USA, Rutgers University, Piscataway, NJ, USA

PHP98 F1 pgA87 COMPARATIVE EFFECTIVENESS RESEARCH (CER) AND ITS EFFECT ON THE HEALTH CARE
DECISION-MAKING ENVIRONMENT
Westrich KD, National Pharmaceutical Council, Washington, DC, USA

PHP99 F2 pgA87 EMERGENCY DISEASE SPECTRUM IN CHINA: BASED ON HOSPITAL DATABASE FROM BEIJING
Liu Y, Wu J, Zhang J, Peking university, Beijing, China, 306 hospital of PLA, Beijing, China

PHP100 F3 pgA87 KEY TRENDS IN HEALTHCARE SPENDING IN BRAZIL IN 2015
Saggia M, Asisma, Sao Paulo, Brazil

PHP101 F4 pgA87 COMPARATIVE EFFECTIVENESS, APPROVAL RATES AND PRICING OF DRUGS WITH FDA’S
BREAKTHROUGH THERAPY DESIGNATIONS
Aggarwal S, Topaloglu H, Kumar S, NOVEL Health Strategies, Chevy Chase, MD, USA, GSK, RTP, NC, USA

PHP102 F5 pgA87 THE VALUE OF OTC MEDICINES IN BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)
Ferreira CN, Santana CF, Rufino CS, Pfizer Brasil, São Paulo, Brazil

PHP103 F6 pgA88 PHYSICIAN PERCEPTION OF PHARMACY ADHERENCE BARRIERS IN A COHORT OF MEDICARE
ADVANTAGE PLANS IN TEXAS
PHP104 F7  pgA88 EVALUATING THE OUTCOMES OF A HIGH-RISK MEDICATION INTERVENTION PROGRAM BETWEEN DUAL AND NON-DUAL ELIGIBLE MEDICARE ADVANTAGE BENEFICIARIES

Leung K1, Sendzik J1, Lee GC1,2, Anthem, Norfolk, VA, USA, 2The University of Texas at Austin and UT Health Science Center at San Antonio, San Antonio, TX, USA

PHP105 F8  pgA88 IMPACT OF NEW CHANGES DUE TO AFFORDABLE CARE ACT ON US MARKET ACCESS

Topaloglu H, Aggarwal S1, NOVEL Health Strategies, Chevy Chase, MD, USA

PHP106 F9  pgA88 ARE EU PAYERS ADAPTING BIOSIMILAR PRICING AND REIMBURSEMENT APPROVAL PROCESSES TO OPTIMIZE HEALTHCARE SAVINGS?

Foxon G1, Fox G2, Craddy P1, Remap Consulting, Cheshire, UK, 2Remap Consulting, Bern, Switzerland

PHP107 F10 pgA88 THE WHO-CHOICE COST-EFFECTIVENESS THRESHOLD: A COUNTRY-LEVEL ANALYSIS OF CHANGES OVER TIME

Griffiths M, Maruszczak M, Kusel J, Costello Medical Consulting Ltd., Cambridge, UK

PHP108 F11 pgA88 THE EFFECT OF INNOVATION LAG ON DRUG ACCESS IN TAIWAN

Hsieh C1, Tasi Y1, Chiang Y1, Huang W2, National Yang-Ming University, Taipei, Taiwan, 2National Yang Ming University, Taipei, Taiwan

PHP109 F12 pgA89 OVERVIEW AND IMPORTANCE OF NUB PROCESS FOR MARKET ACCESS OF IN-PATIENT DRUGS AND DEVICES IN GERMANY

Aggarwal S1, Kumar S2, Topaloglu H3, NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PHP110 F13 pgA89 THE POTENTIAL IMPACT OF PRICE ADJUSTMENTS OF A NEW THERAPY IN GERMANY ON OTHER COUNTRIES: A SIMULATION MODELLING EXERCISE


PHP111 F14 pgA89 CURRENT TRENDS IN US AND EUROPEAN PRICING OF UNIQUE BIOPHARMA PRODUCTS

Bajpai SK1, Shields GE2, Institute of Pharmaceutical Management, Yardley, PA, USA, 2BresMed, Sheffield, UK

PHP112 F15 pgA89 WILL FLAT EU PRICING BECOME A REALITY? CONSIDERATIONS FOR THE BIOPHARMA INDUSTRY AND WHETHER FUTURE EU PRICING TRANSPARENCY RULES WILL AFFECT THE CURRENT POSITION

Ranson P1, Hill CA1, Cline H2, Hill CE1, Marshall JD1, Harries M1, MAP BioPharma Limited, Cambridge, UK, 2Pinset Masons LLP, London, UK

PHP113 F16 pgA89 THE VALUE OF NON-RANDOMISED EVIDENCE FOR INFORMING CLINICAL EFFECTIVENESS: AN ASSESSMENT OF HTA REQUIREMENTS AND PUBLISHED GUIDANCE REGARDING THE APPROPRIATENESS OF NON-RANDOMISED DATA

King D, Mitchell S, Dillon R, Lockhart I, Abacus International, Bicester, UK

PHP114 G1  pgA89 A SURVEY OF ISPOR ATTENDEE VIEWS ON THE USE OF ICER AND ACCEPTABLE ICER THRESHOLDS

Kaura S1, Seetashith A2, Ramesh V2, Nanavaty M1, Proach J1, Khan ZM1, Celgene Corporation, Summit, NJ, USA, 2Market Access Solutions LLC, Raritan, NJ, USA

PHP115 G2  pgA90 JAPAN PRICING METHODOLOGY ANALOGUE ASSESSMENT

Park S, Fatoo A, Yampolsky D, Martin de Bustamante M, CBPartners, New York, NY, USA

PHP116 G3  pgA90 LITERATURE REVIEW OF THE USE OF ICER THRESHOLDS IN HEALTHCARE DECISION-MAKING

Kaura S1, Nanavaty M1, Seetashith A2, Nyandege A2, Khan ZM1, Celgene Corporation, Summit, NJ, USA, 2Market Access Solutions LLC, Raritan, NJ, USA

PHP117 G4  pgA90 THE TROUBLE WITH COST-UTILITY HTA BODIES: THEY SHOULD DETERMINE THE PRICE NOT REACT TO IT

Macaulay R, PAREXEL, London, UK

PHP119 G5  pgA90 TRENDS IN BUDGET IMPACT ANALYSIS ACROSS CENTRAL ASIAN COUNTRIES

Kostyuk A1, Akanov A2, Almadiyeva A3, Kazakhstan Medical University for Continuing Education, Astana, Kazakhstan, 2Astan Medical University, Astana, Kazakhstan

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education

PHP120 G6  pgA90 GENDER DIFFERENCES IN THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE AMONG ADULTS WITH MULTIPLE CHRONIC CONDITIONS

Alwhabi M, Sambamoorthi U, West Virginia University, Morgantown, WV, USA

PHP121 G7  pgA91 ATTITUDES TOWARDS COLLABORATION AMONG NURSES AND PHYSICIANS PRACTICING IN NEWLY ESTABLISHED MEDICAL HOMES

Alcuský MJ1, Ferrari L2, Rossi G2, Liu M1, Maio V1, Thomas Jefferson University, Philadelphia, PA, USA, 2Parma Local Health Authority, Parma, Italy
Thorat T, Shi J, Saret CJ, Cohen JT, Neumann PJ, Tufts Medical Center, Boston, MA, USA; 2Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA; 3Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

PHP123 G9 pgA91  COVERAGE OF MEDICAL DEVICES: IS MEDICARE CONSISTENT WITH PRIVATE PAYERS?
Chenoweth MD, Chambers J, Thorat T, Neumann PJ, Tufts Medical Center, Boston, MA, USA; 2Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

PHP124 G10 pgA91  ENROLLMENT IN HEALTH EXCHANGE PLANS IN 2014: THE IMPACT OF KEY VARIABLES ON UPTAKE OF THIS INNOVATION IN AFFORDABLE HEALTHCARE?
Moore R, Lewis C, Decision Resources Group, Nashville, TN, USA

PHP125 G11 pgA91  USE OF GLOBAL DATA SETS TO ASSESS INNOVATION LANDSCAPES IN EMERGING MARKETS
Ondere L, Garfield S, GfK Custom Research, Wayland, MA, USA

PHP126 G12 pgA91  PHARMACY DIRECTORS’ PERCEPTIONS OF ADMINISTRATORS’ AND HEALTH PROFESSIONALS’ ATTITUDES TOWARDS COLLABORATIVE DRUG THERAPY MANAGEMENT (CDTM) IN U.S. HOSPITALS
Mishra P, Thomas III J, Purdue University, West Lafayette, IN, USA

PHP127 G13 pgA92  HOW MANY OUTPATIENT SURGERY BEDS DO WE NEED?
Wong P, Sommer M, Buhs A, HSHS, Belleville, IL, USA

PHP128 G14 pgA92  DOES THE OWNERSHIP AND USE OF MOSQUITO TREATED NETS BY HOUSEHOLD MEMBERS DEPEND ON THE LEVEL OF EDUCATION OF THE HEAD OF HOUSEHOLD? CASE STUDY OF WESTERN KENYA
Alvin MM, Mogere DM, Ministry of Health, Kisii Teaching and Referral Hospital, Kisii, Kenya; 2Great Lakes University of Kisumu, Nairobi, Kenya

PHP130 G15 pgA92  GENERIC COMPETITION AND AUTHORIZED GENERICS IN THE UNITED STATES
Moon J, Nkurunziza J, Jambi A, Seoane-Vazquez E, Qian J, Hansen RA, MCPHS University, Boston, MA, USA; 2Auburn University, Auburn, AL, USA

PHP131 G16 pgA92  GENERIC MEDICINES-PERCEPTIONS AND ATTITUDES OF FUTURE HEALTHCARE DECISION MAKERS IN SOUTHERN KARNATAK
Udupa N, Vohra Y, Ahmed Z, Lavu A, Jain P, Manipal University, Manipal, India; 2Manipal College of Pharmaceutical Sciences, Manipal, India

PHP132 G17 pgA92  PERCEPTIONS AND KNOWLEDGE ON ANTIBIOTIC USE AND RESISTANCE AMONG HIGH SCHOOL STUDENTS AND TEACHERS IN NEW DELHI, INDIA
Kotwani A, Wattal C, Siddiqui Z, Joshi P, V. P. Chest Institute, Delhi, India; 2Sir Ganga Ram Hospital, New Delhi, India; 3University of Delhi, Delhi, India

PHP133 G18 pgA93  GENDER-SPECIFIC SAFETY OUTCOME REPORTS FOR NEW MOLECULAR ENTITY DRUGS
Lee S, Yoo H, Kim S, Koo B, Lee E, Chonnam National University School of Dentistry, Gwangju, South Korea; 2Seoul National University, Seoul, South Korea

PHP134 G19 pgA93  IMPROVEMENTS IN SELF-REPORTED REAL-WORLD DECISION-MAKING ABILITY AFTER COMPLETION OF A COMPARATIVE EFFECTIVENESS RESEARCH CONTINUING EDUCATION CERTIFICATE
Pickering MK, Perfetto EM, Zaghab RW, Ananywu C, Graff JS, Eichelberger B, University of Maryland School of Pharmacy, Baltimore, MD, USA; 2University of Maryland School of Pharmacy, College Park, MD, USA; 3National Pharmaceutical Council, Washington, DC, USA; 4Academy of Managed Care Pharmacy, Alexandria, VA, USA

PHP135 G20 pgA93  PERCEPTIONS OF THE ROLES OF PATIENTS AND PAYERS IN PHARMACEUTICAL MARKET ACCESS
Sendyona S, Choksi P, Odeyemi IA, Toumi M, Université Claude Bernard Lyon 1, Lyon, France; 2Astellas Pharma EMEA, Chertsey, UK

HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs

PHP136 G21 pgA93  TREND ANALYSIS OF TECHNOLOGY APPRAISAL DECISIONS FROM THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) – WHAT FACTORS INFLUENCE THE LIKELIHOOD OF RECOMMENDATIONS?

PHP137 H1 pgA93  HAVE CHANGES TO THE SCOTTISH MEDICINES CONSORTIUM (SMC) PROCESS FOLLOWING THE ROUTLEDGE REVIEW REALLY IMPROVED ACCESS TO ORPHAN MEDICATIONS AND WHAT FACTORS INFLUENCE RECOMMENDATIONS?

PHP138 H2 pgA93  TREND ANALYSIS OF SMC DECISIONS – WHAT FACTORS INFLUENCE THE LIKELIHOOD OF POSITIVE, RESTRICTED AND NEGATIVE RECOMMENDATIONS?
Hill D, Marshall JD, Hill CA, Harries M, MAP BioPharma Limited, Cambridge, UK

PHP139 H3 pgA94  TRENDS IN THE USE OF COST-MINIMIZATION ANALYSIS IN ECONOMIC ASSESSMENTS SUBMITTED
TO THE SMC

PHP140 H4 pgA94 ASSESSING THE QUALITY OF HEALTH ECONOMIC EVALUATIONS PUBLISHED IN JAPANESE SETTINGS: A SYSTEMATIC REVIEW OF 1991-2012 LITERATURE
Sugimoto T1, Kamae I1, Yamabe K2,3 The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 2Takeda Pharmaceutical Company Ltd., Tokyo, Japan

PHP141 H5 pgA94 ROLE OF INDIRECT COMPARISONS IN THE AMNOG EVALUATION PROCEDURE
Bustamante MM, Gambari J, CBPartners, New York, NY, USA

PHP142 H6 pgA94 TREND ANALYSIS OF G-BA DECISIONS – WHAT FACTORS INFLUENCE THE LIKELIHOOD OF RECOMMENDATIONS?
Hill CA, Hill D, Marshall JD, Harries M, MAP BioPharma Limited, Cambridge, UK

PHP143 H7 pgA94 ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS IN 7 ASIA OCEANIA COUNTRIES/REGIONS: COMPARISON OF EVIDENTIARY REQUIREMENTS FOR STANDARD AND ORPHAN DRUGS
Knight JM, Campbell DJ, Meyer KL, Clark RS, Xcenda, Palm Harbor, FL, USA

PHP144 H8 pgA94 TRENDS IN HEALTH TECHNOLOGY ASSESSMENT (HTA) RECOMMENDATIONS FROM THE UK AND GERMANY – A COMPARISON OF G-BA, SMC AND NICE SINGLE TECHNOLOGY APPRAISAL DECISIONS
Hill CA, Hill D, Marshall JD, Harries M, MAP BioPharma Limited, Cambridge, UK

PHP145 H9 pgA95 USE OF REAL WORLD EVIDENCE IN GERMAN AMNOG APPLICATIONS
Altevers J, Borchert K, Mittendorf T, Braun S, Xcenda GmbH, Hannover, Germany

PHP146 H10 pgA95 THE VALIDITY OF THE PROPORTIONAL HAZARDS ASSUMPTION FOR THE META-ANALYSIS OF TIME TO EVENT DATA TO SUPPORT SUBMISSIONS TO HEALTH TECHNOLOGY ASSESSMENT (HTA) AUTHORITIES

PHP147 H11 pgA95 AN ANALYSIS OF RECENT HTA DECISIONS IN TAIWAN AND KOREA: INFLUENCE FROM AUSTRALIA AND THE UK
Sun D1, Duttagupta S2, Yong C2, CBPartners, New York, NY, USA, 2CB Partners, New York, NY, USA

PHP148 H12 pgA95 AN ANALYSIS OF NICE RECOMMENDED IN LINE WITH CLINICAL PRACTICE HEALTH TECHNOLOGY ASSESSMENT DECISIONS

PHP149 H13 pgA95 A COMPARISON OF G-BA’S ADDITIONAL BENEFIT SCORE TO NICE ICERS
Jaksa A, Liden D, Ho Y, Context Matters, New York, NY, USA

PHP150 H14 pgA96 PRACTICAL PROBLEMS OF COMPARATOR SELECTION TO ASSESS COST-EFFECTIVENESS OF NEW DRUGS FOR REIMBURSEMENT DECISION: A QUALITATIVE STUDY IN SOUTH KOREA
Kang H, Lee H, Cho H, Yonsei University, College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Incheon, South Korea

PHP151 H15 pgA96 BUILDING QUALITY IN HTA PROCESS AND DECISION MAKING: CAN KEY PERFORMANCE MEASURES OF GOOD PRACTICES IN HTA BE IDENTIFIED?
Wang T, CIRS, London, UK

PHP152 H16 pgA96 HOW ARE TOPICS SELECTED AND PRIORITIZED BY THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) AND WHAT MIGHT BE THE OPTIONS IF A TECHNOLOGY IS NOT SELECTED?
Ranson P1, Cline H2, Hill CA2, Hill CE2, Marshall JD1, Harries M1, MAP BioPharma Limited, Cambridge, UK, 2Pincent Masons LLP, London, UK

PHP153 H17 pgA96 ACCESS TO MEDICINE, REIMBURSEMENT AND PRICING IN GERMANY: WHAT ARE THE IMPLICATIONS OF AMNOG?
Mueller E, Schmidt E, Schrank L, Neeser K, LASER ANALYTICA, Loerrach, Germany

PHP154 H18 pgA96 EVALUATING GLOBAL EARLY MARKET ACCESS OPPORTUNITIES FOR INNOVATIVE THERAPIES: FOCUS ON JAPAN, UK AND US
Carr DR, Anastasaki E, Bradshaw SE, Market Access Solutions LLC, London, UK

PHP155 H19 pgA96 COMPARISON OF HEALTH TECHNOLOGY ASSESSMENT (HTA) RANKINGS BY GERMAN AND FRENCH HTA AGENCIES
Hu I1, Zheng J2, Hu XH3, University of Southern California, Los Angeles, CA, USA, 2Celgene Corporation, Summit, NJ, USA

PHP156 H20 pgA97 HOW DOES A SMALL OR MEDIUM Sized PHARMACEUTICAL COMPANY PREPARE FOR AND NAVIGATE THE SCOTTISH MARKET?

PHP157 H21 pgA97 PROMOTION OF MOBILE MEDICAL APPS
<table>
<thead>
<tr>
<th>ID</th>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
| PHP158 | I1 | pgA97  **PHYSICIANS' VIEWS ON PHARMA ROLE IN REAL WORLD EVIDENCE GENERATION IN POLAND**  
Skrzekowska-Baran I¹, Wierzbicka N¹, Zmieko S², Janssen-Cilag Polska, Warsaw, Poland, ²Sequence HC Partners, Warsaw, Poland |                                                                                                                                                                                                        |
| PHP159 | I2 | pgA97  **IS SPATIAL SEGREGATION BY INCOME ASSOCIATED WITH SELF-REPORTED DISABILITY IN CHILE?**  
EXPLORATORY ANALYSIS USING A POPULATION-BASED SURVEY  
Zito P¹, Cabieses B², Complejo Asistencial Barros Luco, Santiago, Chile, ²Universidad del Desarrollo, Santiago, Chile |                                                                                                                                                                                                        |
| PHP160 | I3 | pgA97  **MULTIPLE CHRONIC CONDITIONS AND BMI: POPULATION ESTIMATES FOR HEALTH DECISION MAKING IN PUERTO RICO**  
Amill A¹, Serrano R², González E², Pérez-Perdomo R³, Puerto Rico Department of Health, San Juan, PR, USA, ³Johns Hopkins, Baltimore, MD, USA, ³Centro de Diabetes para Puerto Rico, San Juan, PR, USA |                                                                                                                                                                                                        |
| PHP161 | I4 | pgA97  **THE RELATIONSHIP BETWEEN DISABILITY AND MIGRATION STATUS IN CHILE: PRELIMINARY ANALYSIS FROM REPEATED CROSS-SECTIONAL SURVEY**  
Cabieses B, Delgado I, Bernales M, Obach A, Universidad del Desarrollo, Santiago, Chile |                                                                                                                                                                                                        |
| PHP162 | I5 | pgA97  **SOCIAL AND HEALTH VULNERABILITY OF INTERNATIONAL IMMIGRANTS IN CHILE: PRELIMINARY FINDINGS FROM A SPATIAL ANALYSIS USING 2002-2012 CENSUS DATA**  
Vasquez A¹, Cabieses B², Aragay M², McIntyre AM², Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Universidad del Desarrollo, Santiago, Chile |                                                                                                                                                                                                        |
| PHP163 | I6 | pgA97  **CHILEAN VALUATION OF THE EQ-5D HEALTH STATES**  
Zarate V¹, Kind P², Universidad de los Andes, Santiago, Chile, ²University of Leeds, Leeds, UK |                                                                                                                                                                                                        |
| PHP164 | I7 | pgA98  **AN EVALUATION OF THE USE OF ANTIBIOTICS IN A TEACHING HOSPITAL IN BAHAWALPUR**  
Ahmad M, Bashir A, Farooq Z, Pervaiz F, Akhtar M, The Islamia University of Bahawalpur, Bahawalpur, Pakistan |                                                                                                                                                                                                        |
| PHP165 | I8 | pgA98  **PROSPECTIVE STUDY ON PRESCRIPTION PATTERN IN TERTIARY CARE HOSPITAL IN SOUTH INDIA**  
Sirisha S¹, Goluguri RR², Varghese A¹, Thomas SM¹, Naik V³, Karnataka college of pharmacy, Bangalore, India, ³Karnataka college of pharmacy, Bangalore, India |                                                                                                                                                                                                        |
| PHP166 | I9 | pgA98  **EVALUATION OF KNOWLEDGE, ATTITUDES, AND PRACTICES OF HEALTHCARE PROVIDERS TOWARDS NUTRITION SUPPORT IN PAKISTAN**  
Iqbal MS¹, Bahari MB², Iqbal MZ², Iqbal MW³, Nasir S¹, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan, Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, ²Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, ³Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, ⁴Faculty of Law, University of Malaya, Kuala Lumpur, Malaysia, ⁵Nishtar Hospital, Multan, Pakistan |                                                                                                                                                                                                        |
| PHP167 | I10 | pgA99  **TRENDS IN USE OF HEALTH ECONOMIC EVIDENCE FOR DEVELOPING CLINICAL GUIDELINES**  
Aggarwal S¹, Kumar S², Topaloglu H³, NOVEL Health Strategies, Chevy Chase, MD, USA, ³GLOBAL ACCESS Monitor, Bethesda, MD, USA |                                                                                                                                                                                                        |
| PHP168 | I11 | pgA99  **EFFECTIVENESS OF INTERVENTIONS FOR DRUG PRESCRIBING IMPROVEMENT IN PRIMARY HEALTH CARE**  
Zavala-González MA, Cabrera-Pivalar CE, Orozco-Valerio MJ, University of Guadalajara, Guadalajara, Mexico |                                                                                                                                                                                                        |
| PHP169 | I12 | pgA99  **THE ROLE OF VOLUNTARY HEALTH INSURANCE FUNDS IN SELF-CARE IN HUNGARY**  
Turscányi K¹, Csákávi T¹, Boncz I², University of Pécs, Zalaegerszeg, Hungary, ²University of Pécs, Pécs, Hungary |                                                                                                                                                                                                        |
| PHP170 | I13 | pgA99  **WHEN CAN PHARMACEUTICAL COMPANIES COMMUNICATE HEALTH ECONOMIC CLAIMS TO PAYERS? 10 CASE STUDIES**  
Neumann PJ¹, Saret Cj², Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA, ²Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA |                                                                                                                                                                                                        |
| PHP171 | I14 | pgA99  **IMPLEMENTATION OF NICE CLINICAL GUIDELINES (CG) – WHAT CAN BE LEARNED FROM A UK CASE STUDY AND HOW TO ENSURE THAT HEALTH SERVICES DO NOT FALL SHORT OF THEIR OBLIGATIONS**  
Ranson P¹, Cline H², Hill CA¹, Hill CE¹, Marshall JD¹, Harries M¹, MAP BioPharma Limited, Cambridge, UK |                                                                                                                                                                                                        |
IRRATIONAL DRUG USE PATTERN IN HOSPITALS. A WARNING FOR HEALTH CARE SYSTEM
Umer Jan S,University of Balochistan, Quetta, Pakistan

HEALTH CARE USE & POLICY STUDIES - Risk Sharing/Performance-Based Agreements

FORMULARY MANAGEMENT OF BRANDED DRUGS WITH AND WITHOUT BOXED WARNINGS WITHIN THERAPEUTIC CATEGORIES

KEY MILESTONES OF PUBLIC-PRIVATE PARTNERSHIPS FOR DRUGS IN BRAZIL
Saggia M, Asigma, Sao Paulo, Brazil

OUTCOMES-BASED PRICING AND REIMBURSEMENT ARRANGEMENTS FOR PHARMACEUTICAL PRODUCTS IN THE US AND EU-5: PAYER AND MANUFACTURER EXPERIENCE AND OUTLOOK

EVALUATION OF A PHARMACEUTICAL RISK-SHARING AGREEMENT WHEN PATIENTS ARE SCREENED FOR THE PROBABILITY OF SUCCESS
Mahjoub R, Odegaard F, Zaric GS, University of Alberta, Edmonton, AB, Canada, Western University, London, ON, Canada

CURRENT SITUATION OF THE PUBLIC-PRIVATE PARTNERSHIPS FOR DRUGS IN BRAZIL
Saggia M, Asigma, Sao Paulo, Brazil

HEALTH CARE USE & POLICY STUDIES - Conceptual Papers

TWO-PART PRICING FOR PATENT PROTECTED MEDICINES – AN ECONOMIC ANALYSIS FROM A SWEDISH HEALTH CARE PERSPECTIVE
Hertzman PG, Holm J, Health Access Agency, Zurich, Switzerland, Lund University, Lund, Sweden

INTRODUCTION FOR THE LATEST DEVELOPMENT OF CHINESE PEDIATRIC MEDICINE
Liu M, Huang L, Zhao D, Xu L, AstraZeneca (China), Beijing, China, AstraZeneca (China), Beijing, China

A SYSTEMATIC QUANTITATIVE APPROACH TO INCORPORATING THE PATIENT PERSPECTIVE INTO HEALTH TECHNOLOGY ASSESSMENT DECISION MAKING
Glase KM, Walters NB, Stephenson TM, Vines R, Millman S, Rose J, Fifer S, Janssen Australia, Macquarie Park, Australia, Rare Cancers Australia, Bowral, Australia, Lymphoma Australia, Westlake, Australia, Institute for Choice, North Sydney, Australia

CROWDSOURCING HEALTHCARE TECHNOLOGY INNOVATION: THE USE OF OPEN COMPETITIONS TO PURSUE NOVEL HEALTHCARE TECHNOLOGY SOLUTIONS
Ko JJ, Karagiannis TS, Tran M, Obi EN, Scott & White Health Plan, East Hanover, NJ, USA, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Scott & White Health Plan, Austin, TX, USA, Rutgers University, Piscataway, NJ, USA

ANALYSIS OF ETHICAL THEORIES AND PRINCIPLES EMBEDDED IN HOLISTIC MCDA: A PRIMER TO ETHICS-BASED APPRAISAL OF VALUE IN HEALTHCARE
Goetghbeur MM, Wagner M, Bond K, Hofmann B, LASER Analytica & University of Montreal, Montreal, QC, Canada, LASER Analytica, Montreal, QC, Canada, Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, Institute of Health and Society, Oslo, Norway

COMPARISON OF MACHINE LEARNING, STATISTICAL AND HYBRID METHODS TO IDENTIFY PREDICTORS OF POSITIVE TREATMENT OUTCOMES IN COMORBID CONDITIONS USING EMR DATA
Lipovich I, Griner BP, Niemira J, Jin C, Quintiles, Morrisville, MA, USA, Quintiles, New York, NY, USA, Quintiles, Cambridge, MA, USA

THE COUNTRY ARCHETYPE MODEL:UNLOCKING THE DOOR TO GLOBAL MARKET ACCESS
Moore R, Cox J, Decision Resources Group, Nashville, TN, USA, Decision Resources Group, London, UK

A SITUATION ANALYSIS OF HEALTH POLICY AND HEALTH TECHNOLOGY ASSESSMENT IN KAZAKHSTAN
Kostyuk A, Akanov A, Karp L, Nurgozhin T, Almadiyeva A, Kazakh Medical University for Continuing Education, Astana, Kazakhstan, Astana Medical University, Astana, Kazakhstan, Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan

THE EMERGING ROLE OF PATIENT-REPORTED OUTCOMES (PROS) IN CLINICAL TRIALS IN INDIA
BN V, Naidu M, Esam H, Badguraj L, Kinra G, Dang A, Velammal Medical College Hospital and Research Institute, Madurai, India, MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

THE PILLARS OF COST-EFFECTIVENESS: A PRACTICAL GUIDELINE FOR NEW TECHNOLOGY COST-
**DISEASE- SPECIFIC STUDIES**

**INDIVIDUAL’S HEALTH - Clinical Outcomes Studies**

**PIH1**  
**K9 pgA103** COMPARING MEDICAL THERAPIES FOR HEAVY MENSTRUAL BLEEDING RELATED TO UTERINE FIBROIDS  
Yao X1, Stewart EA1, Laughlin-Tommaso SK1, Borah BJ1, Heien HC1, Mayo Clinic, Rochester, MN, USA,  
1Mayo Clinic College of Medicine, Rochester, MN, USA

**PIH2**  
**K10 pgA104** ADD BACK THERAPY USE AMONG ENDOMETRIOSIS PATIENTS INITIATING LEUPROLIDE ACETATE (LA) THERAPY: ASSOCIATION WITH IMPROVED ADHERENCE AND LOWER SURGERY RATES IN A COHORT OF COMMERCIALLY INSURED WOMEN  
Soliman AM1, Bonafe de MM2, Farr AM3, Castelli-Haley J4, Winkel C4, AbbVie Inc., North Chicago, IL, USA,  
2Truven Health Analytics, Cambridge, MA, USA,  
3Truven Health Analytics, Bethesda, MD, USA,  
4Georgetown University School of Medicine, Washington, DC, USA

**PIH3**  
**K11 pgA104** THE IMPACT OF PARENTS’ KNOWLEDGE AND PRACTICE ON THEIR CHILDREN IMMUNIZATION TIMELINESS: EXPERIENCE FROM MALAYSIA  
Awadh AI1, Hassali MA2, Al-lela OQ3, Bux SH4, Universiti Sains Malaysia (USM) and International Islamic University Malaysia (IIUM), Pulau Pinang, Malaysia,  
3Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia,  
4University of Duhok (UOD), Duhok, Iraq,  
1International Islamic University Malaysia (IIUM), Kuantan, Pahang, Malaysia

**PIH4**  
**K12 pgA104** SAMPLE STRUCTURE IN A PROSPECTIVE STUDY OF 22,000 WOMEN USING HORMONE REPLACEMENT THERAPY (HRT) RETAINED UNBIASED AFTER A FIVE-YEAR FOLLOW-UP  
Eichmann F1, Klamert A, Po thoff P, Kanitscheider C, Kantar Health Germany, Munich, Germany

**PIH5**  
**K13 pgA104** FACTORS AFFECTING IMMUNIZATION TIMELINESS IN MALAYSIA  
Awadh AI1, Hassali MA2, Al-lela OQ3, Bux SH4, Universiti Sains Malaysia (USM) and International Islamic University Malaysia (IIUM), Pulau Pinang, Malaysia,  
3Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia,  
4University of Duhok (UOD), Duhok, Iraq,  
1International Islamic University Malaysia (IIUM), Kuantan, Pahang, Malaysia

**PIH6**  
**K14 pgA104** ANTIMUSCARINIC MEDICATION USE IN ELDERLY OVERACTIVE BLADDER PATIENTS  
Kachru N1, Chatterjee S, Aparasu R, University of Houston, Houston, TX, USA

**PIH7**  
**K15 pgA104** FACTORS AFFECTING PARENTS’ KNOWLEDGE AND PRACTICE ABOUT CHILDHOOD IMMUNIZATION: EXPERIENCE FROM MALAYSIA  
Awadh AI1, Hassali MA2, Al-lela OQ3, Bux SH4, Universiti Sains Malaysia (USM) and International Islamic University Malaysia (IIUM), Pulau Pinang, Malaysia,  
3Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia,  
4University of Duhok (UOD), Duhok, Iraq,  
1International Islamic University Malaysia (IIUM), Kuantan, Pahang, Malaysia

**PIH9**  
**K16 pgA105** PREVALENCE AND PREDICTOR OF ANTIDEPRESSANTS USE DURING PREGNANCY IN THE US: AN NHANES STUDY
PIH10 K17 pgA105 DEVELOPMENT, VALIDATION, AND ANALYSIS OF A LINEAR REGRESSION MODEL PREDICTING CHILD’S BIRTHWEIGHT FROM MOTHER’S RACE, EDUCATION LEVEL, SMOKING STATUS, AND GESTATION AGE
Smolen HJ1, Yuan M2, Hawthorne ME2, Wang Q2, Kelton K1,1, Medical Decision Modeling Inc., Indianapolis, IN, USA, 2Indiana University-Purdue University Indianapolis, Indianapolis, IN, USA

PIH11 K18 pgA105 ASSOCIATION OF OUTDOOR AIR POLLUTION AND STILLBIRTH RISK IN ULAANBAATAR, MONGOLIA
Undram L, Gantuya D, Erkhembataar T, Chimedsuren O, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

PIH12 L1 pgA105 THE USE OF ANTIBIOTICS PROPHYLAXIS FOR INTRATHecal BACLOFEN PUMP PLACEMENT IN PEDIATRICS PATIENTS
Pan I1, Kuo G2, Lam S1,1, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, USA, 2University of California, San Diego, La Jolla, TX, USA

INDIVIDUAL’S HEALTH - Cost Studies

PIH13 L2 pgA105 EXAMINING THE FRACTURE-RELATED COST BURDEN AND HEALTHCARE RESOURCE UTILIZATION POST-MENOPAUSE IN THE U.S. MEDICARE POPULATION
Xie L1, Keshishian A1, Du J1, Baser O2, STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA

PIH14 L3 pgA105 ADMINISTRATION COST OF PEDIATRIC VACCINATION: A FOCUSED LITERATURE REVIEW
Mokiou S, de Cock E, UBC: An Express Scripts Company, London, UK

PIH15 L4 pgA106 ECONOMIC IMPACT OF CERVICAL CANCER AND ANOGENITAL WARTS IN THE MEXICAN HEALTH SYSTEM
Pastor-Martinez V, Perez Bolde-Villarreal C, Jimenez-Aranda P, Merck Sharp & Dohme, Mexico, Mexico

PIH16 L5 pgA106 ANALYSIS OF TREATMENT COST FOR UTERINE FIBROIDS IN UKRAINE
Piniazhko O1, Zalis’ka O1, Vernikovskyi I2, Gnatyshak L2, Got N3, Danylko Halysky Lviv National Medical University, Lviv, Ukraine, 2Lviv Regional Perinatal Center, Lviv, Ukraine, 3Lviv Regional Clinical Hospital, Lviv, Ukraine

PIH18 L6 pgA106 COST-EFFECTIVENESS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN KAZAKHSTAN
Bektur C, Nurgozhi T, Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan

PIH19 L7 pgA106 IMPLICATIONS OF EMPLOYER COVERAGE OF CONTRACEPTION: COST-EFFECTIVENESS OF CONTRACEPTION UNDER AN EMPLOYER MANDATE
Canestaro WJ, Vodicka E, Downing D, University of Washington, Seattle, WA, USA

PIH20 L8 pgA107 SMALL BENEFITS OF THIRD TRIMESTER CHECK-UP AMONG PREGNANT WOMEN POSITIVELY SCREENED FOR THYROID DISORDERS
Bartakova J1, Jiskra J2, 1st Faculty of Medicine Charles University in Prague, Prague 2, Czech Republic, 2General Faculty Hospital in Prague, Prague 2, Czech Republic

PIH21 L9 pgA107 MODELLING THE COST DETERMINANTS FOR OLDER PERSONS’ TRANSITIONS IN CARE (OPTIC)
Kudinga BM, McCabe C, Cummings G, University of Alberta, Edmonton, AB, Canada

PIH22 L10 pgA107 COST-EFFECTIVENESS OF CYP2D6 GENOTYPING IN OLDER DEPRESSED PATIENTS, STARTING WITH NORTRIPTYLINE THERAPY
Berm EJ1, Gout-Zwart JJ1, Luttjebroer J1, Maring JG2, Wilffert B1, Postma MJ1, University of Groningen, Groningen, The Netherlands, 2Dicaonessen Hospital Meppel & Bethesda Hospital Hoogeveen, Meppel, The Netherlands

PIH23 L11 pgA107 ECONOMETRICS ANALYSIS OF NON-PRESCRIPTION MEDICINES EXPENDITURE AT COMMUNITY PHARMACIES IN MALAYSIA
Mohamad Yahaya AH1, Shafie AA2, Hassali MA2, 1Hospital Teluk Intan, Teluk Intan, Perak, Malaysia, 2Universiti Sains Malaysia, Penang, Malaysia, 3Universiti Sains Malaysia (USM), Pulau Pinang, Malaysia

INDIVIDUAL’S HEALTH - Patient-Reported Outcomes & Patient Preference Studies

PIH24 L12 pgA107 MEDICATION ADHERENCE AND HEALTH EXPENDITURE COMPARISON OF ATENOLOL AND METOPROLOL IMMEDIATE AND EXTENDED RELEASE FORMS
Adhikari K, Hastings T, Vaidya V, University of Toledo, Toledo, OH, USA

PIH25 L13 pgA107 A SYSTEMATIC REVIEW OF THE USE OF THE TIME PREFERENCE MODEL TO EXPLORE MEDICATION ADHERENCE BEHAVIOR
Mezgebe M, Lovett AW, Mercer University, Atlanta, GA, USA

PIH26 L14 pgA108 A COMPREHENSIVE SURVEY OF MANAGED CARE ORGANIZATION (MCO) MEDICATION ADHERENCE INTERVENTION PROGRAMS
Jones C1, Sullivan I1, Bayer JC2, Ng K1, Piracha F1, Boice MH2, Coutts DJ2, Mazlish S1, Nagarian A1, Alex SP1, Phani S1, Shah K1, Sheth A1, Sip K1, Van Kempen T1, Basu-Roy UK2, AliazHealth, New York, NY, USA, 2The Solution Lab, Inc., New York, NY, USA, 3The Solution Lab, New York, NY, USA
PIH45 M15 pgA111 CAN A WEB-BASED TOOL TO FACILITATE COMMUNICATION BETWEEN PATIENT AND HEALTHCARE PROVIDERS IMPROVE PATIENT-REPORTED OUTCOMES?
Cleverley D, Personal Healthcare Information, Pittstown, NJ, USA

PIH46 M16 pgA111 PATIENT REPORTED OUTCOMES: ARE THEY RELEVANT TO U.S. PAYERS?
Bayliss M, Hughes TE, Optum, Lincoln, RI, USA, 2Optum, Scottsdale, RI, USA

PIH47 M17 pgA111 FOR TWO COMPANIES THE FDA PRO GUIDANCE LEADS TO SIMILAR BUT DIFFERENT MEASURES: A CASE STUDY IN PSORIASIS
Mordini M, Brown TM, McLeod L, DeMuro C, Gnanasakthy A, RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA

PIH48 M18 pgA111 SWITCHING IN PART D PRESCRIPTION PLAN: PLAN SWITCHING VERSUS BRAND NAME DRUG SWITCHING
Basu R, Baylor Scott & White Health, Temple, TX, USA

PIH49 N1 pgA111 A CONCEPTUAL FRAMEWORK FOR TRANSLATING PATIENT-REPORTED OUTCOMES FOR IMPLEMENTATION IN CLINICAL PRACTICE AND QUALITY IMPROVEMENT EFFORTS
Jeswani N, Gaur P, Ganesan N, Mitchell K, Avalere Health, Washington, DC, USA

PIH50 N2 pgA112 CHOOSING BETWEEN THE PROMIS GLOBAL AND EQ-5D FOR COMPARATIVE EFFECTIVENESS RESEARCH: ARE THEY REALLY DIFFERENT?
Runge SK, Craig BM, Moffitt Cancer Center, Tampa, FL, USA

PIH51 N3 pgA112 IMPACT OF SYMTOMATIC BURDEN AMONG WOMEN DIAGNOSED WITH UTERINE FIBROIDS ON HEALTH-RELATED QUALITY OF LIFE: AN ASSESSMENT USING UTERINE FIBROID SYMPTOM AND QUALITY OF LIFE QUESTIONNAIRE (UFS-QOL)
Soliman AM, Margolis MK, Castelli-Haley J, Coyne KS, 1AbbVie Inc., North Chicago, IL, USA, 2Evidera, Bethesda, MD, USA

PIH52 N4 pgA112 HEALTH RELATED QUALITY OF LIFE IN PATIENTS USING COMPLEMENTARY ALTERNATIVE MEDICINE (HOMEOPATHY) IN QUETTA, PAKISTAN
ul Haq N, Akram A, Iqbal Q, Naseem A, Mohammad S, Ahmed N, Farooqui M, University of Balochistan, Quetta, Pakistan, 2Universiti Teknologi MARA (Bertam campus), Penang, Malaysia

PIH53 N5 pgA112 FACTORS IMPACTING PERSONALIZED MEDICINE TEST ADOPTION: EVALUATING PATIENT PREFERENCES AND WILLINGNESS TO PAY

INDIVIDUAL'S HEALTH - Health Care Use & Policy Studies

PIH54 N6 pgA112 IMPACT OF PEDIATRIC REGULATION ON AVAILABILITY OF NEONATE DRUG INFORMATION
Lindberg-Springs S, Nambari S, Seoane-Vazquez E, 1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2MCPHS University, Boston, MA, USA

PIH55 N7 pgA113 IMPACT OF THE PATIENT PROTECTION AND AFFORDABLE CARE ACT CONTRACEPTIVE COVERAGE MANDATE ON UTILIZATION OF REFILLABLE AND LONG-ACTING REVERSIBLE CONTRACEPTIVES
Vlahiotis A, Tian Y, Iyengar R, 1Express Scripts, St. Louis, MO, USA, 2Express Scripts Holding Company, St. Louis, MO, USA

PIH56 N8 pgA113 PREVALENCE AND DETERMINANTS OF USE OF POTENTIALLY INAPPROPRIATE MEDICATIONS IN ELDERLY INPATIENTS: STOP AND START CRITERIA
Boya C, Goud T, Spurthy R, Kathnoon R, Ravindra R, CES college of pharmacy, kumool, India

PIH57 N9 pgA113 EVALUATING FRACTURE-RELATED EXPENSES AND HEALTH CARE RESOURCE UTILIZATION AMONG POST-MENOPAUSAL WOMEN IN THE U.S. MEDICAID POPULATION
Xie L, Keshishian A, Wang Y, Baser O, 1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA

PIH58 N10 pgA113 EVALUATION OF THE POTENTIAL IMPACT OF DRUG-GENE INTERACTION RISK (DGIR) ON HEALTH RESOURCE UTILIZATION (HRU)
Bress A, Unni S, Biltaji E, Sass RS, Mamiya T, Ye X, Yu B, Biskupiak JE, Brixner D, 1University of Utah, Salt Lake City, UT, USA, 2Genelex, Inc, Seattle, WA, USA

PIH59 N11 pgA113 MEASURING SPENDING TRENDS FOR THOSE WITH EMPLOYER-SPONSORED INSURANCE USING ADMINISTRATIVE DATA
Marder WD, Moldwin E, Pickens GT, 1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Chicago, IL, USA

PIH60 N12 pgA113 TEMPORAL TREND IN USE OF PERMANENT FEMALE STERILIZATION PROCEDURES AND CHARACTERISTICS OF WOMEN WHO UNDERGO THEM IN A COMMERCIALLY-INSURED POPULATION IN THE U.S
Carney P, Lin J, Xia F, Law A, 1Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 2Novosys Health,
<table>
<thead>
<tr>
<th>PMH1</th>
<th>N17</th>
<th>pgA114</th>
<th>GENDER DISPARITIES IN MIGRAINE PHARMACOTHERAPY: APPLICATION OF PROPENSITY SCORE-MATCHED ANALYSES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lai L, Sanabria S, Nova Southeastern University, Davie, FL, USA, Nova Southeastern University, Ft. Lauderdale, FL, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH2</th>
<th>N18</th>
<th>pgA114</th>
<th>TREATMENT PATTERNS OF WOMEN DIAGNOSED WITH UTERINE FIBROIDS 5 YEARS PRE AND POST DIAGNOSIS: A LONGITUDINAL RETROSPECTIVE CLAIMS ANALYSIS OF A COMMERCIALLY INSURED POPULATION IN THE US</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Soliman Am, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C, AbbVie Inc., North Chicago, IL, USA, Analysis Group, Inc., Boston, MA, USA, Georgetown University School of Medicine, Washington, DC, USA</td>
</tr>
</tbody>
</table>

**MENTAL HEALTH - Clinical Outcomes Studies**

<table>
<thead>
<tr>
<th>PMH3</th>
<th>O1</th>
<th>pgA115</th>
<th>THE IMPACT OF ALTERNATIVE ANTIPSYCHOTIC MEDICATIONS ON THE RISK OF ADVERSE EVENTS IN PATIENTS TREATED FOR SCHIZOPHRENIA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jiang Y, Park S, McCombs J, University of Southern California, Los Angeles, CA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH4</th>
<th>O2</th>
<th>pgA115</th>
<th>THE IMPACT OF ALTERNATIVE ANTIPSYCHOTIC MEDICATIONS ON THE RISK OF ADVERSE EVENTS IN PATIENTS TREATED FOR BIPOLAR DISORDERS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jiang Y, Park S, McCombs J, University of Southern California, Los Angeles, CA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH5</th>
<th>O3</th>
<th>pgA115</th>
<th>A RETROSPECTIVE COHORT STUDY USING CLAIMS DATABASE TO INVESTIGATE THE ACTUAL SITUATION IN TREATMENT OF PANIC DISORDER IN JAPAN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Asami Y, Kuribayashi K, Hoshino Y, Yamamoto Y, Nagayasu S, Yamazaki T, Fujimoto Y, Pfizer Japan Inc., Tokyo, Japan, MinaCare co.ltd, Tokyo, Japan, Pfizer Japan Inc, Tokyo, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH6</th>
<th>O4</th>
<th>pgA115</th>
<th>DEPRESSION TREATMENT PATTERNS AMONG INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Deb A, Sambamoorthi U, West Virginia University, Morgantown, WV, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH7</th>
<th>O5</th>
<th>pgA115</th>
<th>ANTIPSYCHOTICS FOR TREATMENT OF PEDIATRIC SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF SYMPTOM CONTROL, WEIGHT GAIN AND DISCONTINUATION DUE TO ADVERSE EVENTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PMH8</th>
<th>O6</th>
<th>pgA116</th>
<th>RELATIVE EFFICACY AND TOLERABILITY OF VORITOXETINE COMPARED WITH SELECTED ANTIDEPRESSANTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER WITH AN INADEQUATE RESPONSE TO PRIOR THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Diamond F, Painchault C, Brignone M, Lundbeck SAS, Paris, France, Keyrus Biopharma, Levallois Perret, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH9</th>
<th>O7</th>
<th>pgA116</th>
<th>MEASURING THE EFFECTS OF REFORMULATING OXYCONTIN ON OPIOID ABUSE IN 6 NATIONAL ABUSE SURVEILLANCE SYSTEMS IN THE US</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Coplan PM, Chilcoat H, Purdue Pharma L.P., Stamford, CT, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH10</th>
<th>O8</th>
<th>pgA116</th>
<th>SYSTEMATIC REVIEW WITH QUALITATIVE ASSESSMENT OF ANTIDEPRESSANT MONOTHERAPIES IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER WITH AN INADEQUATE RESPONSE TO A PRIOR SSRI OR SNRI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Brignone M, Painchault C, Diamond F, Lundbeck SAS, Paris, France, Keyrus Biopharma, Levallois Perret, France</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH11</th>
<th>O9</th>
<th>pgA116</th>
<th>PAROXETINE USE AND COGNITION IN ELDERLY NURSING HOME PATIENTS WITH DEPRESSION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bali V, Aparasu R, Chen H, Johnson M, Camahan R, Chatterjee S, University of Houston, Houston, TX, USA, University of Iowa College of Public Health, Iowa, IA, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH12</th>
<th>P1</th>
<th>pgA116</th>
<th>SELF-REPORTED DEPRESSION AND PRESCRIPTION OF ANTIDEPRESSANTS; DOES GENDER MATTER?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Thunander Sundbom L, Bingefors K, Isacson D, University of Gävle, Gävle, Sweden, Uppsala University, Uppsala, Sweden</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PMH13</th>
<th>P2</th>
<th>pgA116</th>
<th>EXAMINING PREVALENCE, INCIDENCE AND MORTALITY RATES AMONG OPIOID-DEPENDENT PATIENTS IN THE U.S. MEDICARE POPULATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Green Brook, NJ, USA, Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA</td>
</tr>
</tbody>
</table>
Li L, Shrestha S, Baser O, Yuce H, Wang L, STATinMED Research, Plano, TX, USA, STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, City University of New York & STATinMED Research, New York, NY, USA

PMH14 P3 pgA117 PREVALENCE, AWARENESS AND BURDEN OF MAJOR DEPRESSIVE DISORDER IN URBAN CHINA

PMH15 P4 pgA117 PREVALENCE AND INCIDENCE RATES AMONG ALCOHOL-DEPENDENT PATIENTS IN THE U.S. MEDICARE POPULATION
Li L, Shrestha S, Baser O, Yuce H, Wang L, STATinMED Research, Plano, TX, USA, STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, City University of New York & STATinMED Research, New York, NY, USA

PMH16 P5 pgA117 TRENDS IN THE PREVALENCE OF DEMENTIA AMONG THE MEDICARE BENEFICIARIES: 2001-2010
Lu K, Yuan J, University of South Carolina, Columbia, SC, USA

PMH17 P6 pgA117 SOCIO-ECONOMIC FACTORS ASSOCIATED WITH PRE-NATAL ALCOHOL INGESTION IN COASTAL GHANA: A CROSS-SECTIONAL STUDY IN 2014
Da Pilma JL, Davies-Teye BB, Vanootoo L, Dako-Gyekye P, School of Public Health University of Ghana, Accra, Ghana, Drifney Consult Ltd, Accra, Ghana, Greater Accra Regional Health Directorate Ghana Health Services, Accra, Ghana

PMH18 P7 pgA117 SOCIOECONOMIC STATUS AND DEPRESSION IN JAPAN
Takahashi O, Onde S, Deshpande G, St. Luke's Life Science Institute, Tokyo, Japan

PMH19 P8 pgA118 REDUCTION IN ER VISITS OF ADHD PATIENTS: EFFECT OF LONG AND SHORT-ACTING STIMULANTS
Yucel A, Patel J, Pise MN, University of Houston, Houston, TX, USA, The University of Texas School of Public Health, Houston, TX, USA

MENTAL HEALTH - Cost Studies

PMH20 P9 pgA118 REAL-WORLD BUDGET IMPACT ANALYSIS OF ATYPICAL LONG-ACTING ANTI-Psychotics IN FINLAND
Lundberg J, Aalto-Setala M, Otsuka Pharma Scandinavia, Stockholm, Sweden, Lundbeck, Turku, Finland

PMH21 Q1 pgA118 COMPARING THE HEALTHCARE UTILIZATION AND COSTS OF EARLY- AND LATE-STAGE ALZHEIMER'S DISEASE PATIENTS RESIDING IN LONG-TERM CARE FACILITIES
Xie L, Wang Y, Keshishian A, Baser O, STATinMED Research, Ann Arbor, MI, USA, STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA

PMH22 Q2 pgA118 COMPARATIVE ANALYSIS OF PRESCRIPTION UTILIZATION AND COSTS OF LURASIDONE AND Aripiprazole: A PHARMACY-DATABASE STUDY

PMH23 Q3 pgA118 COST OF CARE OF AGITATION AND AGRESSION ASSOCIATED TO DEMENTIA IN 8 EUROPEAN COUNTRIES: RESULTS FROM THE RIGHT TIME PLACE CARE (RTPC) STUDY
Costa N, Wübker A, Biotol I, Demauleon A, Zwakhalen SM, Challis D, Stolt M, Stephan A, Zabalegui A, Saks K, Vellas B, Molinier L, Sauerland D, Soto Martin M, University Hospital of Toulouse, Toulouse, France, Rheinisch-Westfälisches Institut, Essen, Germany, University Hospital of Toulouse, Toulouse, France, Maastricht University, Maastricht, NE, The Netherlands, University of Manchester, Manchester, England, University of Turku, Turku, Finland, Witten/Herdecke University, Witten, Germany, Hospital Clinico de Barcelona, Barcelona, Spain, University of Tartu, Tartu, Estonia, Toulouse University Hospital, Toulouse, France

PMH24 Q4 pgA118 HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH PALIPERIDONE PALMITATE VERSUS ORAL ATYPICAL ANTIpsychotics AMONG PATIENTS WITH SCHIZOAFFECTIVE DISORDER
Pesa JA, Muser E, Montejano LB, Kim G, Smith DM, Janssen Scientific Affairs, LLC, Titusville, NJ, USA, Truven Health Analytics, Ann Arbor, MI, USA

PMH25 Q5 pgA119 CHANGE IN HEALTHCARE UTILIZATION AND COSTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) INITIATING ADJUNCTIVE THERAPY WITH SECOND-GENERATION ANTIPSYCHOTICS (SGAS)
Hagiwara M, Sun SX, Moynahan A, Bornheimer R, Oster G, Policy Analysis Inc. (PAI), Brookline, MA, USA, Forest Research Institute, Jersey City, NJ, USA, Policy Analysis Inc. (PAI) and Managing Co-Director, MINERVA Health Economics Network, Brookline, MA, USA

PMH26 Q6 pgA119 COMPARING HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG SCHIZOPHRENIC PATIENTS WHO INITIATED TYPICAL VS. ATYPICAL LONG-ACTING INJECTABLES IN THE U.S. VETERAN POPULATION
Baser O, Kariburyo MF, Du J, Xie L, STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA, STATinMED Research, Ann Arbor, MI, USA
PMH27 Q7 pgA119 HEALTH RESOURCE USE AND COST ANALYSIS OF SCHIZOPHRENIA PATIENTS PARTICIPATING IN A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, RELAPSE PREVENTION STUDY OF PALIPERIDONE PALMITATE 3-MONTH FORMULATION

Benson C1, Chirila C2, Graham J2, Radder C2, Zheng Q2, Woodruff K3,4, Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2RTi-Health Solutions, Research Triangle Park, NC, USA, 3Janssen Global Services, LLC, Titusville, NJ, USA

PMH28 Q8 pgA119 THE IMPACT OF ANXIETY ON HEALTHCARE UTILIZATION AND COSTS AMONG RESPONDENTS FROM THE CO-MORBIDITIES AND SYMPTOMS OF DEPRESSION (CODE) STUDY

Stephenson JJ5, Grabner M6, Faries D7, Palli SR8, Robinson R8, HealthCore Inc., Wilmington, DE, USA, 4Eli Lilly, Indianapolis, IN, USA, 5CTI Clinical Trial & Consulting, Cincinnati, OH, USA

PMH29 Q9 pgA119 HEALTHCARE RESOURCE UTILIZATION AND COSTS FOR SCHIZOPHRENIA PATIENTS INITIATING ASENAPINE OR ANOTHER BRANDED- ATYPICAL ANTIPSYCHOTIC MEDICATION

Nguyen K1, Chitnis A2, Sun SX2, Dixit S1, Wang R2, Tawah A2, Boulanger L2,3, Forest Research Institute, Jersey City, NJ, USA, 2Evidera, Lexington, MA, USA

PMH30 R1 pgA120 COST OF TAMPERING IN ABUSE OF PRESCRIPTION OPIOIDS

Vietri J1, Masters E2, Barsdorf Al, Mardekan J2, Kantar Health, Horsham, PA, USA, 2Pfizer, Inc., New York, NY, USA

PMH31 R2 pgA120 CHANGES IN HEALTHCARE COSTS ASSOCIATED WITH THE TREATMENT OF BIPOLAR DISORDER FOLLOWING INITIATION OF ASENAPINE VERSUS ARIPIPRAZOLE

Chitnis A1, Wang R1, Sun SX2, Dixit S2, Tawah A1, Boulanger L1,2, Evidera, Lexington, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA

PMH32 R3 pgA120 PRESCRIPTION MEDICATION COSTS ASSOCIATED WITH CHILDHOOD ATTENTION DEFICIT HYPERACTIVITY DISORDER IN AMBULATORY CARE VISITS IN 2010

McConeney RO, Pawar AM, Kogut S, University of Rhode Island, Kingston, RI, USA

PMH33 R4 pgA120 THE BURDEN OF TREATMENT SWITCH IN PATIENTS WITH MAJOR DEPRESSION: A US RETROSPECTIVE ADMINISTRATIVE CLAIMS ANALYSIS

Perez V1, Gauthier G2, Guerin A2, Francois C3, Merkile E1, Takeda Pharmaceuticals International, Inc, Deerfield, IL, USA, 2Analysis Group, Inc., Montreal, QC, Canada, 3Pharmaceuticals, Inc./NA, Richmond, VA, USA

PMH34 R5 pgA120 COST EFFECTIVENESS ANALYSIS OF DIFFERENT TREATMENT ALTERNATIVES IN CHILDREN WITH ATTENTION DEFICIT HYPER ACTIVITY DISORDER (ADHD)

El-Hamamsy M, Elsayed BM, Eid EM, Ain Shams University, Cairo, Egypt

PMH35 R6 pgA121 COST BURDEN ANALYSIS OF RELAPSE IN PRESCRIPTION OPIOID DRUG DEPENDENT PATIENTS TREATED WITH BUPRENORPHINE/NALOXONE AND PATIENTS WITHOUT PHARMACOLOGICAL TREATMENT

Khemiri A1, Zah V2, Khartonova E3, Aballea S3, Ruby J4, Creative- Ceutical, Chicago, IL, USA, 2ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro, 3Creative-Ceutical, Paris, France, 4Reckitt Benckiser Pharmaceuticals, Inc./NA, Richmond, VA, USA

PMH36 R7 pgA121 A COST EFFECTIVENESS ANALYSIS OF PHARMACOLOGICAL AND PSYCHOLOGICAL INTERVENTIONS IN ADULTS WITH OBSESSIVE COMPELLING DISORDER

Bryden P1, Hollingworth W1, Welton NJ1, Caldwell DM1, Skapinakis P2, University of Bristol, BRISTOL, UK, 2University College London, London, UK

PMH37 R8 pgA121 MEDICAL COST-OFFSET OF ONCE-MONTHLY PALIPERIDONE PALMITATE MONOTHERAPY AND ADJUNCTIVE THERAPY IN 15-MONTH TRIAL

Joshi K1, Lin J2, Lingohr-Smith M2, Fu DJ3, Janssen Scientific Affairs, Titusville, NJ, USA, 2Novosys Health, Green Brook, NJ, USA

PMH38 R9 pgA121 A COST-EFFECTIVENESS ANALYSIS OF ANTIPSYCHOTICS FOR TREATMENT OF SCHIZOPHRENIA IN UGANDA

Lubinga S1, Mutamba BB2, Nganizi A3, Babigumira JB4, University of Washington, Seattle, WA, USA, 2Butabika National Referral Hospital for Mental, Neurological and Substance Abuse Disorders, Kampala, Uganda, 3Kadic Hospital, Kampala, Uganda

PMH39 S1 pgA121 ESTIMATING THE COST-EFFECTIVENESS OF VORTIOXETINE VERSUS DESVENLAFAXINE AS FIRST LINE THERAPY FOR MILD TO MODERATE MAJOR DEPRESSIVE DISORDER IN REMITTED PATIENTS

Keyloun KR, Devine B, University of Washington, Seattle, WA, USA

PMH40 S2 pgA121 COST-UTILITY OF VORTIOXETINE VERSUS VENLAFAXINE XR IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN SOUTH KOREA

Jung R1, Brignone M2, Campbell R3, François C4, Milea D4, HyeRang, Seoul, South Korea, 3Lundbeck SAS, Issy-les-Moulineaux, France, 4Mapi Group, London, UK, 5Lundbeck Inc, Deerfield, IL, USA, 5Lundbeck Singapore Pte Ltd, Singapore, Singapore

PMH41 S3 pgA122 A COST-EFFECTIVENESS MODEL TO GUIDE HEALTH POLICY IN BIPOLAR DISORDER TREATMENT

Chatterton ML1, Mihalopoulos C2, Barendregt J3, Berk M1, Mitchell PB4, Khoo J5, Carter R2, Deakin University,
Geelong, Australia, Deakin University, Melbourne, Australia, University of Queensland, Brisbane, Australia, University of New South Wales, Randwick, Australia, Toowong Private Hospital, Toowong, Australia

**PMH42** S4 pgA122 \**HEALTHCARE UTILIZATION AND COSTS AMONG ADULTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH VILAZODONE VS. OTHER SELECTIVE SEROTONIN REUPTAKE INHIBITORS**

Zhou Z1, Sun SX2, Chopra P3, Zhong Y1, Toretv T1, Signorovitch JE3, Analysis Group Inc., Boston, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Analysis Group Inc., Boston, MA, USA

**PMH43** S5 pgA122 \**HEALTH RESOURCE AND CRIMINAL JUSTICE SYSTEM COSTS FOR YOUNG CLINICAL PATIENTS WITH SCHIZOPHRENIA AND PRIOR INCARCERATION BY TREATMENT FAILURE STATUS**

Kozma C1, Muser E2, Benson C3, Mao L1, Starr HL2, Alphs L2, C-K Consulting, St. Helena Island, SC, USA, Janssen Scientific Affairs, LLC, Titusville, NJ, USA, Janssen Research and Development, Titusville, NJ, USA

---

**MENTAL HEALTH - Patient-Reported Outcomes & Patient Preference Studies**

**PMH44** S6 pgA122 \**FIVE-YEAR IMPACT OF DEPRESSION ON LIFE-SATISFACTION AND THE PROTECTIVE INFLUENCE OF SOCIAL SUPPORT**

Potthoff P, Eichmann F, Kanitscheider C, Kantar Health Germany, Munich, Germany

**PMH45** S7 pgA122 \**CAREGIVERS’ PREFERENCES FOR TREATMENT OPTIONS IN ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD): A LATENT CLASS ANALYSIS**

Ng X1, Bridges JF2, Ross MM3, Frosch EJ4, Reeves GM5, dosReis S1, University of Maryland School of Pharmacy, Baltimore, MD, USA, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, Johns Hopkins Hospital, Baltimore, MD, USA, University of Maryland School of Medicine, Baltimore, MD, USA

**PMH46** S8 pgA123 \**QUALITATIVE STUDY OF PATIENTS’ PREFERENCES FOR BIPOLAR DEPRESSION TREATMENT**

Ng-Mak DS1, Poon JL2, Rajagopalan K3, Kleinman L4, Roberts L5, Revicki DA6, Loebel A6, Sunovion Pharmaceuticals, Inc, Marlborough, MA, USA, Evidera, Bethesda, MD, USA, Evidera, Seattle, WA, USA, Sunovion Pharmaceuticals, Inc, Fort Lee, NJ, USA

**PMH47** S9 pgA123 \**RELATIVE EFFICACY AND TOLERABILITY OF VORTIOXETINE VERSUS APPROVED ANTIDEPRESSANTS FOR MAJOR DEPRESSIVE DISORDER: A META-REGRESSION OF CLINICAL TRIALS**

Diamand F1, Danchenko N2, Brignone M3, Rive B4, Perez V5, Ereshefsky L6, Francois C7, Merikle E8, Lundbeck S.A.S. Paris Fr, EU, Paris, France, Analysis Group, Inc., Montreal, QC, Canada, Parexel International, Glendale, CA, USA, Lundbeck LLC, Deerfield, IL, USA, Takeda Pharmaceuticals International, Inc, Deerfield, IL, USA

**PMH48** T1 pgA123 \**A REVIEW OF CLINICAL OUTCOME ASSESSMENTS USED IN FDA APPROVED DRUG LABELS FOR MENTAL HEALTH CONDITIONS**

Pomplius FA1, Lindberg-Springs S1, Seoane-Vazquez E2, Massachusetts College of Pharmacy & Health Sciences, Boston, MA, USA, MCPHS University, Boston, MA, USA

**PMH49** T2 pgA123 \**IMPACT OF MAJOR DEPRESSIVE DISORDER ON PATIENT FUNCTIONALITY AND WORK PERFORMANCE IN EMERGING MARKETS**

Reznik AE1, Sudharshan L1, Stephens JM2, Shelbaya A3, Pappadopulos E4, Haider S2, Lin I2, Gao C2, Pharmerit International, Bethesda, MD, USA, Pfizer, Inc, New York, NY, USA, Pfizer Inc, Groton, CT, USA

**PMH50** T3 pgA123 \**FACTORS AFFECTING HEALTH-RELATED QUALITY OF LIFE IN INDIVIDUALS WITH DEPRESSION**

Shah D1, Anupindi VR2, Vaidya V3, Goodman M, University of Toledo, Toledo, OH, USA

**PMH51** T4 pgA124 \**PSYCHOMETRIC EVALUATION OF DISEASE SPECIFIC HEALTH RELATED QUALITY OF LIFE INSTRUMENTS IN EATING DISORDERS**

Shah S1, Al-Shatnawi S1, Franic DF2, The University of Georgia, Athens, GA, USA

**PMH52** T5 pgA124 \**THE EFFECT OF VORTIOXETINE ON FAMILY FUNCTIONING IN ADULTS WITH MAJOR DEPRESSIVE DISORDER**

Francois C1, Nielsen RZ2, Danchenko N3, Williams V4, Lancon C5, Lundbeck LLC, Deerfield, IL, USA, H. Lundbeck A/S, Valby, Denmark, Lundbeck S.A.S. Paris Fr, EU, Paris, France, RTI Health Solutions, Research Triangle Park, NC, USA, Hospital Sainte-Marguerite, Marseille, France

---

**MENTAL HEALTH - Health Care Use & Policy Studies**

**PMH54** T7 pgA124 \**THE ASSOCIATION OF VALUE-BASED BENEFIT DESIGN AND BEHAVIORAL HEALTH MEDICATION USAGE**

Reid KJ1, Aguilar KM2, Thompson E3, Miller RM4, Cerner, Kansas City, MO, USA, Cerner, Culver City, CA, USA, Children’s Mercy Hospital of Kansas City, Kansas City, MO, USA

**PMH55** T8 pgA124 \**META-REVIEW OF FINDINGS IN EVER LITERATURE REVIEWS COVERING BEHAVIORAL HEALTH-PHYSICAL HEALTH INTEGRATION STUDIES**

Keleti D1, Golinkoff M2, Weaver K3, Michael KE1, Gelzer AD1, The AmeriHealth Caritas Family of Companies, Philadelphia, PA, USA, PerformCare, Harrisburg, PA, USA

**PMH56** T9 pgA125 \**THE RELATIONSHIP BETWEEN PSEUDOEPHEDRINE SALES AND CLANDESTINE METHAMPHETAMINE LABS**

Troske S1, Freeman PR1, Goodin AJ2, Blumenschein K2, Talbert J3, University of Kentucky College of Pharmacy,
PMH57 U1  pgA125 BENZODIAZEPINE USAGE PATTERNS IN RESPONDENTS WITH DEPRESSION FROM THE CO-MORBIDITIES AND SYMPTOMS OF DEPRESSION (CODE) STUDY
Stephenson JJ1, Grabner M1, Faries D2, Palli SR3, Robinson R2, HealthCore Inc., Wilmington, DE, USA, 2Eli Lilly, Indianapolis, IN, USA, 3CTI Clinical Trial & Consulting, Cincinnati, OH, USA

PMH58 U2  pgA125 PATTERNS OF PSYCHOTROPIC PRESCRIPTION UTILIZATION AMONG DISABLED MEDICARE BENEFICIARIES UNDER 65
Qian J1, Wittayakorn S2, Hansen RA1, 1Auburn University, Auburn, AL, USA, 2Auburn University, Harrison School of Pharmacy, Auburn, AL, USA

PMH59 U3  pgA125 USE OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) DRUGS IN CANADA, 2010-2014
Aziz S1, Gillman A2, Griffiths J3, Health Canada, Ottawa, ON, Canada, 1M.S. Brogan, Mississauga, ON, Canada

PMH60 U4  pgA125 AUDIT OF IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI) PRESCRIPTION FOR DEPRESSION IN CURRENT CLINICAL PRACTICE WITHIN THE HEALTH IMPROVEMENT NETWORK (THIN) UK PRIMARY CARE DATABASE

PMH61 U5  pgA126 ANTIPSYCHOTIC UTILIZATION AMONG WASHINGTON STATE DUAL ELIGIBLES
Murphy SM, McPherson S, Layton M, Kennedy J, Washington State University, Spokane, WA, USA

PMH62 U6  pgA126 EVIDENCE FOR THE OFF-LABEL USE OF METHYLPHENIDATE FOR COGNITIVE ENHANCEMENT IN HEALTHY INDIVIDUALS
Brito GV, Vidal JS, Brazilian Ministry of Health, Brasília, Brazil

PMH63 U7  pgA126 ANTIPSYCHOTIC USE AND FOSTER CARE PLACEMENT STABILITY AMONG YOUTH WITH ATTENTION-DEFICIT HYPERACTIVITY/DISRUPTIVE BEHAVIOR DISORDERS
Tai M1, dosReis S2, Shaw T3, 1University of Maryland, School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3University of Maryland, School of Social Work, Baltimore, MD, USA

PMH64 V1  pgA126 UTILIZATION PATTERN OF ANTIPSYCHOTIC DRUGS IN A SOUTH INDIAN TERTIARY CARE HOSPITAL
Rao V1, Madhuma T1, Tallal V1, Subudhi S2, Pattanak S1, Kowkab T1, Ravula R1, 1Talla Padmavathi College of Pharmacy, Warangal, INDIA, WARANGAL, India, 2Talla Padmavathi Pharmacy College, Warangal, WARANGAL, India

PMH65 V2  pgA126 RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH OFF-LABEL USE OF ATYPICAL ANTIPSYCHOTICS IN A COMMUNITY-DWELLING ADULT POPULATION: FINDINGS FROM THE MEDICAL EXPENDITURE SURVEY
Varghese D, Carroll NV, Virginia Commonwealth University, Richmond, VA, USA

PMH66 V3  pgA126 HEALTH RESOURCE USE OF PATIENTS ENROLLED TO JANSSEN CONNECT TREATED WITH LONG-ACTING INJECTABLE (LAI) ATYPICAL ANTIPSYCHOTICS: PRELIMINARY RESULTS FROM A SUMMATIVE EVALUATION
Benson C1, Boulanger L2, Yang E2, Pan X1, Payne K1, Fastenau J1, 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Evidera, Lexington, MA, USA, 3Evidera LLC, Lexington, MA, USA, 4United BioSource Corporation, Bethesda, MA, USA

PMH67 V4  pgA127 MEDICATION USE PATTERNS, HEALTH-CARE RESOURCE UTILIZATION AND ECONOMIC BURDEN FOR PATIENTS WITH SCHIZOPHRENIA IN BEIJING, CHINA
Chen Y1, Cheng Y2, Shi Q2, Yu X3, Liu Q3, Gu X1, Shi J3, Montgomery W1, 1Lilly Suzhou Pharmaceutical Company, Ltd., Shanghai, China, 2Chinese Society of Psychiatry Institute of Mental Health, Peking University, Beijing, China, 3Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China, 4Center for Health Economics and Policy, Tianjin International Joint Academy of Biomedicine, Tianjin, China, 5Eli Lilly Australia Pty Ltd., West Ryde, Australia

PMH68 V5  pgA127 CLINICAL ASPECTS OF INTERNET ADDICTION AMONG STUDENTS: IS IT DISORDER OR TREND OF THE TIMES?
Salpynov Z, Karp L, Salpynov L, Potapchuk Y, Almadiyeva A, Astana Medical University, Astana, Kazakhstan

PMH69 V6  pgA127 RACIAL/ETHNIC DIFFERENCES IN THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE IN ADULTS WITH MEDIUM MENTAL DISTRESS: RESULTS FROM 2012 NATIONAL HEALTH INTERVIEW SURVEY
Rhee TG, Johnson PJ, Evans RL, McAlpine DD, University of Minnesota, Twin Cities, Minneapolis, MN, USA

PMH70 V7  pgA127 AN EXAMINATION OF PATIENTS WITH OBESITY AMONG A NATIONALLY REPRESENTATIVE POPULATION: COMORBIDITY, HEALTHCARE COSTS AND SATISFACTION
Richardson T, Claeys C, Wasserman D, Tomaszewski K, KJT Group, Inc., Honeoye Falls, NY, USA

PMH71 W1  pgA127 USE OF CLOZAPINE AND ANTIPSYCHOTIC POLYPHARMACY AMONG PATIENTS WITH SCHIZOPHRENIA: CHARACTERIZING THE PRESCRIBERS
Tang Y1, Horvitz-Lennon M2, Gellad WF1, Normand ST3, Donohue JM1, 1University of Pittsburgh, Pittsburgh, PA, USA, 2RAND Corporation, Pittsburgh, PA, USA, 3Harvard Medical School, Boston, MA, USA
PMH72  W2  pgA128  PREVALENCE AND CORRELATES OF NON-MEDICAL USE OF PRESCRIPTION STIMULANTS AMONG UNIVERSITY STUDENTS
Shanbhag PP, Nayak R, St. John's University, Jamaica, NY, USA

PMH73  W3  pgA128  CAN SOCIAL NETWORK ANALYSIS BE USED TO IDENTIFY DOCTOR SHOPPERS?
Perry B1, Freeman PR2, Oser CB3, Talbert J1,2 Indiana University, Bloomington, IN, USA, 3University of Kentucky College of Pharmacy, Lexington, KY, USA

PMH74  W4  pgA128  PREVALENCE OF SELF-REPORTED ADULT ADHD SYMPTOMS AMONG UNIVERSITY STUDENTS: A MULTIDISCIPLINARY COMPARISON
Shanbhag PP, Nayak R, St. John's University, Jamaica, NY, USA

PMH75  W5  pgA128  THE CONCENTRATION OF ANTIPSYCHOTIC PRESCRIBING: EVIDENCE FROM MEDICAID
Tang Y1, Chang CH1, Huskamp H2, Gellad WF1, Donohue JM1,1 University of Pittsburgh, Pittsburgh, PA, USA, 2Harvard Medical School, Boston, MA, USA

PMH76  W6  pgA128  IMPACT OF KENTUCKY HOUSE BILL 1 ON CONCURRENT PRESCRIBING OF OPIOID, ALPRAZOLAM, AND CARISOPRODOL
Freeman PR, Troske S, Goodin AJ, Blumenschein K, Talbert J, University of Kentucky College of Pharmacy, Lexington, KY, USA

PMH77  W7  pgA128  PHYSICIAN CARE-PROVIDING BEHAVIOR IN TREATING ATTENTION-DEFICIT HYPERACTIVE CHILDREN AND ADOLESCENTS
Patel A1, Chen H1, Aparasu R1, Ochoa-Perez M2, Chan W2, Sherer J1, University of Houston, Houston, TX, USA, 2Legacy Community Health Services, Houston, TX, USA, 3University of Texas Health Science Center, Houston, TX, USA

PMH78  W8  pgA129  USE OF MULTIPLE CONCURRENT ANTIPSYCHOTICS IN CHILDREN ENROLLED IN THE MISSISSIPPI MEDICAID PROGRAM
Shah R1, Nunna S1, Banahan III B1, Hardwick SP2, Clark JP2, University of Mississippi, University, MS, USA, 2Mississippi Division of Medicaid, Jackson, MS, USA

PMH79  X1  pgA129  TRAJECTORIES OF BUPRENORPHINE TREATMENT AND ASSOCIATED EMERGENCY DEPARTMENT AND INPATIENT USE IN A LARGE MEDICAID PROGRAM
Lo-Ciganic W1, Gellad WF2, Gordon AJ3, Cochran G4, Donohue JM3, University of Arizona, Tucson, AZ, USA, 2University of Pittsburgh, Pittsburgh, PA, USA

PMH80  X2  pgA129  PRESCRIPTION PATTERNS FOLLOWING FIRST-LINE SECOND-GENERATION ANTIPSYCHOTICS FOR PATIENTS WITH SCHIZOPHRENIA IN JAPAN: AN INSURANCE CLAIMS DATABASE ANALYSIS
Jamotte A1, Onishi Y2, Clay E1, Aballea S1, Creativ-Ceutical, Paris, France, 2Creativ-Ceutical K.K., Tokyo, Japan
Looking for poster presentations online?

The ISPOR Scientific Presentations Database is a searchable database of over 31,500 research papers presented at ISPOR meetings since 1998. The database is searchable by disease, topic, meeting, key word and author. To access the database, go to www.ispor.org and click the purple "Scientific Presentations" tab.